



IFCC
International Federation
of Clinical Chemistry
and Laboratory Medicine

Nominations for PRESIDENT

2026 - 2029

CANDIDATES

Nominees

Harald RENZ

Nader RIFAI

Society

Deutsche Gesellschaft
für Klinische Chemie und
Laboratoriumsmedizin /
German Society for Clinical
Chemistry and Laboratory
Medicine (DGKL) - Germany

Association for Diagnostics
& Laboratory Medicine
(ADLM) – USA



Harald RENZ

**DEUTSCHE GESELLSCHAFT
FÜR KLINISCHE CHEMIE UND
LABORATORIUMSMEDIZIN
(DGKL) - GERMANY**



NOMINATION FORM for PRESIDENT IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin DGKL,
Germany.....
(insert name of National Society)

Name: Prof. Mariam Klouche

Office held within the National Society:
Vice President and National Representative

**We nominate for the Office of President for the term 2027-2029
(to begin as President-elect in 2026):**

Prof. Dr. med. Harald Renz
(insert name of nominee)

Signature:.....


Date: 25.06.2025

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, Prof. Harald Renz

accept nomination for election to the position of President.

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics
Philipps University Marburg.....
University Hospitals Giessen and Marburg GmbH

Campus Marburg

Baldingerstrasse.....

35043 Marburg, Germany

Phone: +49 (0) 6421 58 66234.....

Fax:

Email: harald.renz@uk-gm.de

Signature:.....


Date: 16.06.2025

3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues which you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

During my term as IFCC President, I will focus in particular on the following areas and topics:

A Strengthening Laboratory Medicine and Clinical Chemistry as the leading diagnostic medical discipline

Laboratory medicine and clinical chemistry need to be positioned as the leading medical diagnostic discipline. Global healthcare budgets are under increasing pressure and we face increasing competition between all medical disciplines worldwide. During the COVID-19 pandemic, we have impressively demonstrated how important our discipline is. We have high systems' relevance; we must now build on this, not only in the context of **pandemic preparedness**, but far beyond that.

Personalized and Precision Medicine can only be accomplished with our groundwork of **Precision Diagnostics**. We have a huge impact on **patient care, patient safety** and **data quality** with our internal and external quality programmes. Therefore, the goal will be for the IFCC to launch campaigns and initiatives in collaboration with multiple stakeholders, especially in the diagnostics industry.

B Promotion of advanced technologies and test portfolios

With the advent of precision medicine, we are facing huge advancements in many areas of medical laboratory diagnostics. These include platform technologies such as mass spectrometry, sequencing, multiple omics data and deep cellular testing and analysis, to name just a few examples from this field. We need to promote mining of this huge Big Data treasure to improve patient care. **We are in the driver's seat when it comes to implementing Artificial Intelligence in the healthcare sector. With our decades of experience in digital data management, we are well equipped to take on this leading role.** We will launch scientific and educational programmes to promote these topics.

C The importance of Global Health and Global Laboratory Medicine

We will enter into a **new North-South dialogue** with **focus on low- and middle-income countries**. Many of these countries are still far behind in terms of availability, access and use of laboratory medical testing. We will develop and promote activities together with national and **international foundations, global organizations**, also in the form of public-private partnerships. Our Regional Federations will play a pivotal role in these activities. We will reach out to the **United Nations, WHO, national and international governmental organizations (e.g. European Union, African Union, etc.)** to help achieve and support the Sustainability Development Goals (**SDGs**). This includes, in particular, **teaching, training and educational activities**.

D The focus on the next generation of Doctors, Specialists and Scientists

Our discipline is highly dependent on the next generation of doctors, scientists and specialists. We will promote programmes to position our discipline in the context of medical service and we will develop campaigns that can be used in high schools, universities and training centers. In addition, it will be important to launch young leadership programmes. This of course includes **gender equality**. These programmes will be developed together with the council, the federations and our active IFCC members.

I am very much looking forward to working with you all towards these goals. Our IFCC has a bright future ahead of it!

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as President. Font used should be Calibri; font size 11.

In 2011, I had the honour and privilege of serving as **President of The World Congress of Clinical Chemistry and Laboratory Medicine (19th Joint Meeting of International Federation (IFCC), 21st European Federation (EFCC) and 8th German Society (DGKL) of Laboratory Medicine, Berlin, Germany**. At the time, it was the largest and most commercially successful conference. Many of you probably remember this remarkable event, which took place in Berlin, and the great social event in 'Museumsinsel' right in the heart of our capital.

For more than a decade, I have focussed on the national matters of our discipline. From 2010-2016 I served as **President of the DGAKI**. From 2018-2021 I was **Vice President (President-elect) of the DGKL** for two terms, and since 2022 until the end of this year, I have been **President of the DGKL**. This position is linked with the chairmanship of the overseeing board of the **Foundation for Biochemistry and Molecular Diagnostics (SPMD)**, which is one of two institutes operating the external quality programme/proficiency testing in Germany (Reference Institute for Bioanalytics, RfB).

During this decade, I was responsible for a significant transformation in both the Foundation as well as the Scientific Society.

We have emerged from the pandemic as a strong medical society in Germany. One of our key focus areas is the **young Scientist and Specialist**. We are the advocates of the new generation. The young specialists are organized as the "Junge Labor" with many highly active member. We have also achieved **strong financial stability** and reorganized and professionalized our media-outreach to our members, the medical and scientific community and the public.

From 2015 to 2021 I served as **Chief Medical Officer (CMO) of the University Hospitals** of Giessen and Marburg. This allowed me to gain a deep insight into the healthcare system, and this term of office coincided with the COVID 19 pandemic. And so I had to play an important role in crisis management and later on in pandemic preparedness.

With the advent of my regular retirement in early 2027, I now not only have the necessary expertise and skills to run our global organization, but also the full-time commitment required to do so.

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

Since 1999 I have been serving as **Professor and Director of the Institute of Laboratory Medicine at the Philipps University of Marburg, Germany**, which is one of the largest centers of hospital-based laboratory medicine in Germany and provides a comprehensive super specialized service for all disciplines. In parallel, I served as **Chief Medical Officer (CMO) of the University Hospital from 2015 to 2021**. In these two positions, I was able to build an exceptional national and international network with scientific collaborators, national and international health organizations and political stakeholders in government and parliament.

My **research** focuses on **chronic inflammatory non-communicable diseases (NCDs)**, with a special focus on chronic lung disease. My group has made major contributions to the understanding of gene-environment interactions, the role of the microbiome and environmental microbes, the role of epigenetics and neuro-immune interactions. Our current focus is on the impact of **climate change on health**.

In **Sub-Saharan Africa**, we have developed a strong **hospital partnership programme in Tanzania**. Together with the German government, we are building a state-of-the-art **Center of Excellence** to deliver (super) specialized laboratory diagnostics to the Global South.

I am an international leader in the field with a current personal Hirsch factor of **94 (06/2025)**, the publication of **>380** original research papers in peer-reviewed international journals, **>180** review articles and editorials, **>80** book chapters with citations in scientific publications (**Scopus 06/2025 rank 33.129**).

I have held and continue to hold several **Visiting and Guest Professorships within my global network**:

Full Visiting Professor of Pediatrics at **Harvard Medical School** (2011-2012);

Forchheim Visiting Professor at **Hebrew University Jerusalem** (2018); Visiting Professor at **Sechenov University, Moscow** (2020-2022); Visiting and Honorary Professor at **Kilimanjaro Christian Medical Center in Moshi/Tanzania** since 2020) and Visiting Professor at **Tongji Medical School in Shanghai, China** (since 2025).

Training and Education: Over the past 25 years, I have trained numerous medical specialists in laboratory medicine and clinical chemistry, post-doctoral fellows and PhD students. The handbook "Praktische Labordiagnostik" (published by De Gruyter) is in its 4th edition with great success in Germany. It is currently being translated into English.

To summarize, I bring to the position of IFCC President:

- **Exceptional leadership skills on Executive Boards of national and international organizations**
- **Highly successful scientific track record**
- **A vision for the global future of laboratory medicine**
- **A large global network of scientific, governmental and non-governmental stakeholders**
- **Full-time commitment due to retirement**

Das Präsidium

Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin
Geschäftsstelle | Alt-Moabit 96a | 10559 Berlin

IFCC Nominations Committee



DGKL-Geschäftsstellen
Friesdorfer Str. 153 | 53175 Bonn
Alt-Moabit 96a | 10559 Berlin

Präsident
Univ.-Prof. Dr. H. Renz

Vizepräsidentin
Prof. Dr. M. Klouche

Schatzmeister
Prof. Dr. M.F. Bauer, MBA

Schriftführerin
Prof. Dr. J. Schanz

Präsidiumsmitglied
Prof. Dr. U. Ceglarek

Präsidiumsmitglied
Prof. Dr. T. Streichert

Past-Präsident
Univ.-Prof. Dr. M. Nauck

30.06.2025

To IFCC Nominations Chair Prof. Lai

Re: Nomination of Prof. Dr. Harald Renz as IFCC President (2027 – 2029)

It is a great honour and pleasure to nominate Prof. Harald Renz for the position of IFCC President (2027-2029). The Executive Board of the DGKL has unanimously nominated Prof. Harald Renz for this prestigious position.


Prof. Renz is internationally renowned and enjoys the highest recognition around the world. He brings exceptional leadership qualities to this position. He has a highly successful scientific track record. And what we really want to emphasize is a vision for the global future of laboratory medicine together with a large global network of scientific governmental and non-governmental stakeholders.

As he will be retiring at the beginning of 2027, it is also very important for this task that he can commit himself full-time. He will share his extensive and ongoing network of outstanding experts and his continuing engagement in his medical laboratory project in Tanzania with IFCC.

To summarise, it is with the greatest enthusiasm that we endorse his nomination.

If you have any further questions, please do not hesitate to reach out to me and us on the DGKL Executive Board.

Yours sincerely



Prof. Dr. med. Mariam Klouche
Vice-President of the DGKL

Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin e. V.

Kontakt
Tel.: 0228 92 68 95-0 (Bonn)
Tel.: 030 39 40 54-16 (Berlin)
E-Mail: geschaeftsstelle@dgkl.de

Bankverbindung
BBBank Karlsruhe
BIC: GENODE61888
IBAN: DE35 6609 0800 0017 4583 47

Steuernummer
206/5887/1282
Umsatzsteuer-IdNr.
DE 231 466 924

Vereinsregister
HRB VR12527
Amtsgericht Frankfurt am Main
www.dgkl.de



Nader RIFAI

ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (ADLM) - USA



NOMINATION FORM for PRESIDENT IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of Association for Diagnostics and Laboratory Medicine.....
(insert name of National Society)

Name:.....Mark J. Golden.....

Office held within the National Society:National Representative to IFCC.....
(This should normally be the nominated National Representative to the IFCC Council)

**We nominate for the Office of President for the term 2027-2029
(to begin as President-elect in 2026):**

.....Nader Rifai.....
(insert name of nominee)

Signature:.....


Date:6/11/2025.....

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, ...Nader Rifai.....
(insert name)

accept nomination for election to the position of President.

and accept the obligations and time commitment required for this position, if elected.
My contact details are:

Address: Boston Children's Hospital.....
..... Department of Laboratory Medicine.....
..... 300 Longwood Avenue.....
..... Boston, MA 02115, USA.....

Phone: +1 617 767-8324.....

Fax:

Email: nader.rifai@childrens.harvard.edu.....

Signature:
 Date:May14, 2025.....

3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues which you see as important for the IFCC and how you might address them. Font use should be Calibri; font size 11.

Nader Rifai, originally from Damascus, Syria, is a Professor of Pathology at Harvard Medical School, The Orah S. Platt Chair in Laboratory Medicine, and the Director of Clinical Chemistry at Boston Children's Hospital in the US, as well as an Adjunct Professor of Medicine at University of Porto in Portugal.

I bring to the IFCC presidency ~40-y experience in academic laboratory medicine, vast network of international experts, proven record of creating and leading large innovative programs in research and education, and an ability to collaborate with professionals from different cultures and backgrounds. The topics I consider a focus in my tenure include:

Promotion of the Profession and the Practice of Laboratory Medicine

- Promote the profession of laboratory medicine and its value, not only in the delivery of health care but also in the creation of innovative diagnostic tools and concepts
- Make IFCC the leader in developing and implementing applications of novel digital technologies in laboratory medicine
- Continue to promote the IFCC's standardization and harmonization activities but create the necessary mechanisms to implement the resulting standards in routine clinical testing

Enhancing Educational Activities

- Modernize IFCC's approach to creating educational materials by employing novel technologies such as AI and promoting contemporary learning concepts such as adaptive learning, the closest to personalized education
- Work toward raising the standard of laboratory medicine professionals by providing multilingual and region-targeted educational and training materials
- Work with national societies to facilitate the adoption of the IFCC CE/CPD (PROCEED) in their countries as a credible source of continuing education credits

Improving Practices Within IFCC

- Strengthen relationship and dialogue with the IVD industry for the benefit of the profession while preserving the core values of IFCC
- Enhance Young Scientists programs and promote their integration within the organization
- Increase collaboration among IFCC Divisions to better implement the organization's goals
- Strengthen relations with organizations such as WHO, CDC, BIPM, and NIST and clinical societies
- Create a mechanism to enhance collaboration and exchange of ideas among the various IFCC federations
- Assure the viability and success of the WorldLab and EuroMedLab congresses, scientifically and financially
- Restructure the role of the IFCC President from being primarily ambassadorial to a task- and goals-driven one. Reorient the focus of the Executive Board from being tactical to strategic with its business conducted in a transparent and collegial manner. Reinvigorate conflict of interest policies to assure that all those involved in IFCC comply with the highest ethical standards to protect the integrity of the organization

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as President. Font used should be Calibri; font size 11.

National and International Societies:

Throughout my career, I have been active in scientific societies, primarily AACC (now ADLM) and IFCC. My most significant activities at AACC include the Chair of Lipids and Lipoproteins Division, Vice-Chair of two Scientific Annual Meetings, and serving on the Board of Directors; I published several books with AACC Press, including Handbook of Lipoprotein Testing and the Biochemical Basis of Pediatric Disease. I also served on the Board of Directors of the American Board of Clinical Chemistry and the National Academy of Clinical Biochemistry. In addition, I served on multiple committees of the NIH, CDC, and FDA; I was a voting member for four years on the FDA panel that rendered decisions regarding suitability of new laboratory tests and devices for clinical use in the US and was instrumental in the CDC-sponsored international efforts to standardize hsCRP assays. In addition, I participated in writing the CDC/American Heart Association-sponsored clinical guidelines for the use of inflammatory markers in cardiovascular disease. I have been active in IFCC for ~30 years, starting with standardization activities, most notably of Lp(a). I served on the Scientific Committees of three WorldLab congresses and as a member of the Scientific Division. I have been active in the Education and Management Division for eight years and acting as its Chair for the past five years.

National and International Awards:

Over the years, I have been recognized for my accomplishments by numerous awards from national and international organizations, most notably the IFCC Howard Morris Distinguished Clinical Chemist Award and the AACC Outstanding Lifetime Achievement Award, the two highest honors of the two societies. I also received from these two organizations their top awards recognizing Excellence in Education. In 2024, I received the honoris causa degree of Doctor of Science from the State University of New York for my "Contribution to Science and Medicine", a rarely granted honor to individuals in the field of laboratory medicine.

Summary:

I have clearly demonstrated a vast experience working in leadership position in national and international organizations as well as in governmental agencies. The international scientific and medical communities recognized the significance of these contributions by bestowing on me various accolades. I bring to the IFCC presidency the experience to lead with integrity and honor and the ability to create a cohesive team to implement my vision and goals.

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

Below is a summary highlighting some of my major academic accomplishments:

1. Research Activities

My initial research focused on exploring the role of lipoproteins in atherogenesis; the apolipoproteins assays I developed remain in clinical and commercial use four decades later. Subsequently, I concentrated on understanding the role of inflammatory biomarkers, most notably hsCRP, in coronary disease employing large clinical trials and epidemiologic cohorts. My work resulted in remarkable discoveries that changed the practice of preventive cardiology. According to WoS, my work accumulated 90,763 citations and my *h*-index is 132; 19 of my papers were cited >1000 times.

2. Clinical Chemistry

I served as the Editor-in-Chief of *Clinical Chemistry* from 2008 to 2022 during which the impact factor rose from 4.89 to 12.17 and numerous innovative educational features were added. These educational materials were then housed on the *Clinical Chemistry* Trainee Council, a multilingual and free of charge website that was used by >15,000 individuals from 153 countries. Furthermore, I made articles from *Clinical Chemistry* available to national societies to translate and publish in their own journals; >3,000 translations in 17 languages were generated. This activity led to the launching of the Chinese version of *Clinical Chemistry* in 2017.

3. Learning Lab for Laboratory Medicine

In 2015, I initiated the Learning Lab for Laboratory Medicine, an AI-driven educational program that is based on the concept of adaptive learning. Learning Lab is endorsed by the IFCC and provided free of charge for individual users. In 2023, the Learning Lab received the Comenius EduMedia Award for innovative use of technology in medical education. Learning Lab contains 125 curriculum-based advance courses (~13,000 learning objectives) and 95 courses that are designed specifically for MLS and is currently being translated to nine languages. >500 international experts participated in building this program that is currently used by >17,000 individuals from 156 countries.

4. Tietz Textbook of Laboratory Medicine

In 2014, I assumed responsibility for this Textbook and since increased its scope to encompass all disciplines of laboratory medicine and introduced the concept of *Platform*, of which the Textbook is only a component. The Platform includes clinical cases, podcasts, animation films, questions banks, atlases, etc. >250 international experts contributed to this endeavor. In 2024, This product received the Textbook Excellence Award from TAAA for its innovative concept. I also edited two editions of the Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, widely used by university students.



June 10, 2025

Prof. Leslie Lai
Chair
IFCC Nominations Committee's Chair
IFCC

RE: ADLM's Nomination of Dr. Nader Rifai, Ph.D. for the Position of President of the IFCC

Dear Prof. Lai:

As the National Representative to the IFCC Council, I am pleased to inform you that the ADLM is nominating Dr. Nader Rifai, Ph.D. for the position of IFCC President, based on his leadership and long-standing service to the field of laboratory medicine.

Dr. Rifai received his Ph.D. in Clinical Chemistry, Medical College of Virginia, Richmond in 1985. Over the years he has served in numerous academic and hospital positions. He has been deeply involved in the work of ADLM and IFCC, including service on the ADLM Board and in committees across both organizations.

If you have any questions, you may contact me directly or Kerry Cosby (kcosby@myadlm.org), Director of Global Affairs.

Sincerely yours,



Mark J. Golden
Chief Executive Officer



IFCC
International Federation
of Clinical Chemistry
and Laboratory Medicine

Nominations for **SECRETARY**

2027 - 2029

CANDIDATES

Nominees

Tony BADRICK

Tahir PILLAY

Sedef YENICE

Zhen ZHAO

National Society

Australasian Association for
Clinical Biochemistry and
Laboratory Medicine (AACB) -
Australia

South African Association
for Clinical Biochemistry and
Laboratory Medicine (SAACB) –
South Africa

Turkish Biochemical Society
(TBS) – Türkiye

Association for Diagnostics &
Laboratory Medicine (ADLM) –
USA



Tony BADRICK



AUSTRALASIAN ASSOCIATION FOR CLINICAL BIOCHEMISTRY AND LABORATORY MEDICINE (AACB) - AUSTRALIA



NOMINATION FORM for SECRETARY IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of Australasian Association for Clinical Biochemistry and Laboratory Medicine.....
(insert name of National Society)

Name:.....Greg Ward.....

Office held within the National Society:AACB President.....
(This should normally be the nominated National Representative to the IFCC Council)

We nominate for the Office of Secretary for the term 2027-2029

...Tony Badrick.....
(insert name of nominee)

Signature:.....*Greg Ward*.....

Date:02/06/2025.....

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I,Tony Badrick.....
(insert name)

accept nomination for election to the position of Secretary.

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: Royal College of Pathologists of Australasia Quality Assurance Programs,
8 Herbert Street, St Leonards, New South Wales, Australia, 2065.

Phone: +61(0) 435 416 022.....

Fax: ...+61 2 9356 2003.....

Email: ...tony.badrick@rcpaqap.com.au.....

Signature:*Tony Badrick*..... Date: .1st June.2025.....



3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues which you see as important for the IFCC and how you might address them. Font use should be Calibri; font size 11.

Tony Badrick, CEO of the Royal College of Pathologists Quality Assurance Programs, Adjunct Professor, School of Pharmacy and Pharmacology, Griffith University, Gold Coast; Honorary Associate Professor, National Centre for Epidemiology and Public Health, Australian National University College of Health and Medicine and ANU College of Science; Honorary Associate Professor, Faculty of Medicine, Bond University, Gold Coast; Visiting Fellow, Australian Institute for Health Innovation, Macquarie University.

My experience includes senior management in a large private pathology laboratory, a medium-sized not-for-profit EQA organisation, and academic work. For over ten years, I chaired the Document Review and Liaison Committee of the Australian National Pathology Accreditation Advisory Council (NPAAC), the Australian Pathology system regulator.

I have been the President of the Asia-Pacific Federation of Clinical Biochemistry and Laboratory Medicine (APFCB) and chairperson of the Education and Laboratory Management Committee from 2010 until 2024. This region has 60% of the world's population and enormous diversity in language, resources, wealth, political, cultural, and healthcare systems.

With this experience and skill set, my focus as secretary of the IFCC would be the **resource-limited members**. It is advantageous to come to the IFCC with a relatively new set of eyes to lead organisational change.

Promotion of the Profession and the Practice of Laboratory Medicine

Promote the profession of laboratory medicine and its value to **laboratory regulators**

Enable the IFCC to provide accessible tools and training in critical laboratory medicine techniques to **resource-limited countries** to reduce analytical error and cost

Work with the IVD industry to improve **standardization and harmonization activities**.

Enhancing Educational Activities

Create educational materials to support the **competence** of laboratory staff, particularly in **resource-limited countries**

Increase access to the Professional Exchange Programs for mid-career scientists from **resource-limited countries**

Focus on basic laboratory activities such as **innovative concepts of QC and EQA depending on the allowed regional resources**

Improving Practices Within IFCC

Strengthen relationships and dialogue with the IVD industry, particularly the **newer players from the Asia Pacific region**

Clearly define and communicate the organization's goals and how the strategic plan will deliver them

Concentrate resources on the goals set out in the strategic plan (Quality, Clinical outcomes and Cost-effectiveness)

Assure that the IFCC office has the needed resources to optimally support the activities of the organization

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as Secretary. Font used should be Calibri; font size 11.

Australasia

I have been heavily involved with the Australian Association for Clinical Biochemistry and Laboratory Medicine (AACB) and the Australian Institute for Clinical and Medical Scientists (AIMS) for many years, serving as President of the AACB and Vice President (Director) of AIMS. Supporting the community of medical scientists is vital for individual growth, education, and professionalism. I have formally been involved with developing the Faculty of Science of the Royal College of Pathologists of Australasia (RCPA) since 2009, including Chair (2012-2019) and, since 2017, the Chief Examiner. I have been closely involved with developing and implementing the training curriculum and the governance of the faculty.

International

In my service with the APFCB, I have coordinated new initiatives such as a Chemical Pathology course, Lean training, various symposia and visiting lecturers. During this time, I was an invited speaker in India, China, Nepal, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Vietnam, Mongolia, the Philippines, Sri Lanka, Taiwan, South Korea, Argentina, Japan, USA, France, Norway, Israel, New Zealand, Croatia, Slovenia, Italy, Greece, UK, Finland, Spain, Malawi, Turkey, Austria, Republic of Ireland and the Czech Republic.

I am active in the European Organisation for External Quality Assurance Providers (EQALM) and chair the PoCT Working Party. I also served as the Chair of the Traceability, Education, and Promotion Working Group of the Joint Committee for Traceability in Laboratory Medicine (JCTLM).

IFCC

I have served on several IFCC working groups for over twenty years, including the Environmental Policy Committee, Harmonisation of Interpretative Comments, Value of Pathology, Analytical Quality, Traceability in Laboratory Medicine, Machine Learning, and Laboratory Environmental Impact of Laboratory Medicine. I convened the International Federation of Clinical Chemistry and Laboratory Medicine Working Group on implementing Patient-Based Real-Time Quality Control.

I have been an IFCC visiting lecturer in 2009 (Vietnam), 2011 and 2014 (Philippines), 2020 (Malawi), and 2023 (Sri Lanka).

I have served as a Member of the IFCC Executive Board as the Asia Pacific Regional representative since 2024.

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

Qualifications

BAppSc (MLS), BSc, BA, MBA, PhD (QUT), PhD (UQ), FAACB, FAIMLS.

Educational activities

I have lectured undergraduate and postgraduate students at the Australian National University, Queensland University of Technology, Griffith University, Bond University, University of Queensland, and Macquarie University. I am active with the medical and clinical scientist trainee education for the RCPA.

I have been an examiner for the AACB (including Chief Examiner), the AIMS, and the RCPA with medical and scientific candidates.

Regulatory Activities

I have served on various NPAAC for over twenty years, including 14 NPAAC Standard drafting committees, of which I chaired 7.

Research Activities

I have presented over 400 papers at scientific meetings, published over 250 papers in referred journals, and written 10 book chapters related to quality management, quality control, and external quality assurance.

Environmental Impact of Medical Laboratories

I have also been raising awareness of the environmental impact of clinical laboratories since 2012.

Professional Activities

Other areas where I have been involved with development include the scientific workforce. Since 2009, I have been associated with developing Competency-Based Standards, a Scope of Practice, and government-funded projects involving career pathways, certification, and competence assessment for Australian medical scientists. I was the Chair (Director) of the Board of the Australian Council for the Certification of the Medical Laboratory Workforce, which has implemented a Certification scheme.

Awards

1983 Wellcome Prize - Best candidate in MAACB examination; 1988 Wellcome Prize - Best candidate in FAACB examination; 2003 AACB Roman Travelling Lectureship; 2005, 2023 Dr TN Pattabiraman Orator Award Lecture (Association of Clinical Biochemists of India) - Inaugural Orator; 2006 AIMS Saal Foley Lectureship; 2006 Australian Defence Medal - Service to Army Reserve; 2007 Honorary Fellow of the Royal College of Pathologists of Australasia; 2008 AACB Outstanding Service Medallion. Distinguished Fellow Award (RCPA).

In 2022, I was appointed a Member of the Order of Australia (AM) for significant service to diagnostic pathology in leadership roles and to education.



**AUSTRALASIAN ASSOCIATION FOR CLINICAL
BIOCHEMISTRY AND LABORATORY MEDICINE**

OFFICE: 5/85 Bourke Rd, Alexandria NSW, 2015
PO Box 7336, Alexandria NSW, 2015
Telephone: +61 2 9669 6600 Email: office@aacb.asn.au

2 June 2025

IFCC Office
E: ifcc@ifcc.org

Letter of support for Prof Tony Badrick, for nomination to the IFCC Executive Board, 2027-2029

Dear IFCC

The Australasian Association for Clinical Biochemistry and Laboratory Medicine (AACB) is pleased to nominate **Prof Tony Badrick** for the position of **Secretary of the IFCC Executive Board for the 2027–2029 term**.

Prof Badrick has made significant contributions to laboratory medicine at national, regional, and global levels. In Australia, he has been deeply involved with both the AACB and the Australian Institute for Clinical and Medical Scientists (AIMS), serving as President of AACB and Vice President (Director) of AIMS. He has also played a key leadership role in the Faculty of Science of the Royal College of Pathologists of Australasia (RCPA) since 2009.

Internationally, as President of the Asia-Pacific Federation of Clinical Biochemistry and Laboratory Medicine (APFCB), Professor Badrick launched numerous initiatives, such as training programmes in Chemical Pathology and Lean methodology, and has represented the field globally, delivering invited lectures in over 30 countries across five continents.

He is active in the European Organisation for External Quality Assurance Providers (EQALM) as Chair of the PoCT Working Party and has served with the Joint Committee for Traceability in Laboratory Medicine (JCTLM) as Chair of the Traceability, Education, and Promotion Working Group. Within the IFCC, Prof Badrick has contributed to a wide array of working groups over more than two decades, including those on Environmental Policy, Analytical Quality, Machine Learning, and Patient-Based Real-Time Quality Control, which he convened. He has also served as an IFCC visiting lecturer in multiple countries and is currently a Member of the IFCC Executive Board, representing the Asia-Pacific region since 2024.

With his extensive experience, strong leadership, dedication, and forward-thinking approach, the AACB believes that Prof Badrick is the ideal candidate for IFCC Secretary.

Regards



Mr Greg Ward
President, AACB

Australasian Association for Clinical Biochemistry and Laboratory Medicine
P: (02) 9669 6600 | M: +61 408904524 | W: www.aacb.asn.au

Affiliated with the

*INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE
ASIA-PACIFIC FEDERATION FOR CLINICAL BIOCHEMISTRY AND LAB MEDICINE*



Tahir PILLAY

SOUTH AFRICAN ASSOCIATION FOR CLINICAL BIOCHEMISTRY AND LABORATORY MEDICINE (SAACB) - SOUTH AFRICA



NOMINATION FORM for SECRETARY IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of South African Association for Clinical Biochemistry & Laboratory Medicine ...
(insert name of National Society)

Name: ... Prof Rivak Punchoo

Office held within the National Society: President

We nominate for the Office of Secretary for the term 2027-2029

..... Prof Tahir Pillay

Signature: 

Date: ...28 June 2025.....

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, Tahir Pillay

accept nomination for election to the position of Secretary.

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: Department of Chemical Pathology, University of Pretoria, Faculty of Health Sciences, Pathology Building, Corner Bophelo & Dr Savage Roads, Arcadia, Pretoria, South Africa

Phone: ...+27-83-275-5977.....

Fax: ...+27-12-328-3600.....

Email: tspillay@gmail.com

Signature:  Date:28 June 2025.....

3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues which you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

As a long-standing member of the global laboratory medicine community, I have witnessed the transformative role that the IFCC plays in advancing diagnostic science, education, and healthcare worldwide. My intent is to build on this foundation by enhancing its global impact, inclusivity, and sustainability. In an increasingly complex and interconnected world, the IFCC must remain agile, innovative, and representative of all its members, especially those in under-resourced regions.

1. Enhancing Global Equity in Laboratory Medicine

One of the most pressing challenges is the disparity in laboratory infrastructure, training, and diagnostic access across regions. I intend to advocate for initiatives that support capacity building, training, and mentorship in low- and middle-income countries (LMICs). My experience in training a large cohort of African chemical pathologists and my leadership in organizing congresses and workshops in LMIC settings demonstrate my ability to bridge global inequalities. I will work to establish regional centres of excellence, promote twinning programmes, and expand access to digital learning through the IFCC eAcademy and other tools.

2. Strengthening Communication and Engagement

Effective communication within and beyond IFCC is vital to its influence and cohesion. As former IFCC eNews Editor and current Chair of the Communications and Publications Division, I have overhauled the Federation's communication platforms and enhanced its global visibility. If elected, I will continue to drive innovation in communication strategy—improving multilingual access, increasing engagement across time zones, and strengthening visibility of member society activities. Clear, timely communication builds trust and enables collaboration.

3. Ensuring Financial Sustainability and Strategic Partnerships

For the IFCC to fulfill its expanding mandate, it must have a solid financial foundation. Drawing on my experience in dramatically improving the financial position of the South African national society (SAACB), I will advocate for new funding strategies, including revenue-generating educational programmes, partnerships with private industry, and philanthropic engagement. I will also support efforts to expand corporate and affiliate membership, including from sectors such as biotechnology, artificial intelligence, and telemedicine, which increasingly intersect with laboratory medicine.

4. Promoting Innovation and Scientific Advancement

The rapid pace of innovation in diagnostics—driven by molecular technologies, artificial intelligence, and data analytics—presents an opportunity for the IFCC to lead. I will encourage the formation of new task forces and working groups that can explore emerging technologies and recommend best practices. My own research on nanobody-based diagnostics is an example of how innovation can directly address healthcare needs, particularly in resource-limited environments.

5. Prioritising Education and Young Scientist Development

Investing in the next generation of laboratory professionals is vital to the IFCC's future. I will promote global scholarships, research exchanges, and increased involvement of young scientists in IFCC governance and initiatives. By leveraging digital platforms and inclusive curricula, we can build a more connected and empowered workforce.

Conclusion

The IFCC stands at a pivotal moment—called to respond to global challenges while fostering scientific excellence and equitable healthcare. With your support, I aim to contribute vision, experience, and a collaborative spirit to help lead the IFCC into its next chapter. (498 words)

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as Secretary. Font used should be Calibri; font size 11.

I have held numerous national and international leadership roles that position me well for the role of Secretary of the IFCC. Within the IFCC, I have served in the Communications and Publications Division (CPD) since 2012, initially as a member of the CPD executive committee and Editor of the IFCC eNews (2012–2017). In this role, I led a major transformation of the eNews and introduced a newsflash format to enhance member communication. From 2018 onward, I have served as Chair of the CPD, becoming the first person from Africa to lead an IFCC division in its (then) 70-year history. Under my leadership, we raised the profile of the IFCC eJournal, attaining PubMed and Scopus indexing and submitting for Web of Science inclusion.

As Co-President and Scientific Programme Chair of IFCC WorldLab Durban 2017—the first ever on the African continent—I demonstrated strong organizational skills, engaging stakeholders across continents to deliver a world-class event. I have also served on the scientific programme committee for IFCC WorldLab Seoul 2020.

Nationally, I served as President of the South African Association for Clinical Biochemistry & Laboratory Medicine (SAACB), after having been its Secretary and Communications Officer. Under my leadership, SAACB's financial reserves increased tenfold in two years, and its international engagement has grown significantly. I have also served as Secretary of the College of Pathologists in South Africa (2014–2017), and chief examiner in Chemical Pathology.

In 2024, following an international search by the Royal College of Pathologists (RCPATH), London, I was appointed as **Clinical Director of International Activities for the RCPATH**. I was also appointed to the **Executive council of the Global Consortium for Engineering in Medicine** started by the University of Illinois, Urbana-Champaign.

These cumulative experiences have provided me with a nuanced understanding of governance, communication, and organizational dynamics—core to the role of Secretary. I bring deep familiarity with IFCC administrative structures and workflows, and have built strong relationships with member societies, regional federations, and the Executive Board.

My prior success in managing large-scale projects, leading communication initiatives, and fostering global partnerships will directly contribute to maintaining transparent records, supporting Executive Board operations, and enhancing engagement across IFCC constituents. My multicultural experience and cross-continental professional network further position me to represent and serve a globally diverse membership.

I am fully committed to the responsibilities and time required for the role, and honoured to be considered for this important position. (400 words)

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

My principal professional and scientific interests lie at the intersection of laboratory medicine, molecular diagnostics, and medical education, with a strong emphasis on innovation, global health equity, and capacity building in low- and middle-income countries. These interests have guided my career across academia, clinical practice, international collaboration, and scientific publishing.

Scientifically, my primary focus has been on the molecular cell biology of insulin signaling, insulin resistance, and the application of molecular modeling and recombinant DNA technologies to develop novel diagnostic tools. I am currently pioneering the use of nanobodies—small, single-domain antibody fragments—for affordable, high-performance point-of-care diagnostic tests, particularly aimed at addressing the burden of non-communicable diseases such as diabetes mellitus in resource-constrained settings. I am also developing projects in the use of big data analysis for laboratory medicine for the definition of reference intervals and for patient-based real-time quality control. This work directly supports the IFCC's commitment to advancing clinical diagnostics and fostering global access to quality testing.

Professionally, I am deeply committed to capacity development through education and mentorship. I have authored two widely used digital textbooks—Practical Clinical Chemistry: Core Concepts and Interactive Mathematics for Laboratory Medicine—and contributed chapters to Tietz Textbook of Laboratory Medicine and Tietz Fundamentals. These initiatives reflect my drive to improve global access to high-quality, digitally accessible learning resources, aligned with the IFCC's mission to promote education and training in laboratory medicine.

Clinically, I have led national training programmes and supervised the development of numerous African chemical pathologists, reflecting a sustained commitment to professional development in underserved regions. My extensive involvement with national and international professional bodies—including as Chair of the IFCC Communications and Publications Division, Editor-in-Chief of the Journal of Clinical Pathology, and President of the SAACB—demonstrates a passion for improving laboratory standards, scientific communication, and global collaboration.

My previous interests strongly align with and contribute to the mission of the IFCC by supporting standardisation, innovation in diagnostic development, excellence in education, and equitable global outreach. I have always sought to leverage scientific advancement not only for academic prestige but also for societal benefit—particularly in advancing diagnostics where the need is greatest.

As IFCC continues to evolve in a turbulent world, my translational research focus, advocacy for digital education, and dedication to strengthening laboratory services in low-resource settings will contribute directly to its mission to improve healthcare worldwide through laboratory medicine.(394 words)

SAACB

Enquiries: saacb1@gmail.com Website: <http://www.saclinpath.co.za/>



The South African Association for Clinical Biochemistry and Laboratory Medicine

28 June 2025

Professor Leslie Lai
Chair, IFCC Nominations Committee
International Federation of Clinical Chemistry and Laboratory Medicine
Via Carlo Farini 81
20159 Milano, Italy

Dear Professor Lai

Subject: **Support letter for nomination of Prof Tahir S. Pillay as IFCC Secretary**

It is my greatest pleasure on behalf of the SAACB to nominate Prof Tahir S. Pillay, the immediate past President of SAACB and past chair of the IFCC Communications and Publication Division (CPD), to the position of IFCC Secretary for the term 2027 -2029. We believe that Prof Pillay has unique skills and experience to be a great servant leader to the IFCC and the executive board and to enable the IFCC to ascend to even greater heights.

Prof Pillay is a highly capable, academically accomplished and astute person whose leadership is well recognized and he is involved in a number of national and international committees. Within the IFCC, he was previously a member of the CPR committee and then appointed to the CPD executive committee where he was eNews editor for two terms. He made a large impact on the eNews and was responsible for revamping the newsletter amongst other initiatives, including the e-Journal. Subsequently, in recognition of his leadership capabilities, he was appointed chair of the Communications & Publications Division, the first time that any individual from the African continent has led a division of the IFCC in the 70 years, since inception in 1952.

Since taking over as SAACB national society president, he has made tremendous contributions and significant improvements to the organization, including raising appreciable funds for the national society and building sound international relationships within the scientific community. He is well known across all of the IFCC regions and has cultivated good relationships with the society leadership in many of the member countries. Prof Pillay is an efficient organizer and has been responsible for some of the most successful national South African conferences and workshops, skills that will serve well within the IFCC. He was also co-president of the first IFCC Worldlab to be held in Africa, IFCC Worldlab 2017 in Durban and which was acknowledged to be a highly successful debut Worldlab conference for Africa.

On a personal level, he has more than the required management, communication and interpersonal skills to lead the organisation. With his excellent communication skills and diverse background and experience, as well as his multicultural knowledge of Africa, Asia, Europe, the Americas and beyond, we have no doubt that Prof Tahir Pillay will bring new and progressive developments to the IFCC.

Kind regards,



Prof Rivak Punchoo
President, SAACB

Enquiries: saacb1@gmail.com Website: <http://www.saclinpath.co.za/>



Sedef YENICE

**TURKISH BIOCHEMICAL
SOCIETY (TBS) - TÜRKIYE**



NOMINATION FORM for SECRETARY IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by the National Society

On behalf of the Turkish Biochemical Society.
(insert name of National Society)

Name: DOĞAN YÜCEL

Office held within the National Society: President of the Turkish Biochemical Society
(This should normally be the nominated National Representative to the IFCC Council)

We nominate for the Office of Secretary for the term 2027-2029

SEDEF YENICE (IFCC National Representative to Turkish Biochemical Society)
(insert name of nominee)

Signature: 

Date: ...JUNE 28, 2025.....

A recent picture should be provided; however, a full curriculum vitae is not required.

2. Acceptance by Nominee

I, ...SEDEF YENICE.....
(insert name)

Accept nomination for election to the position of Secretary.

And accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: Gayrettepe Florence Nightingale Hospital, Gayrettepe Mah.
Cemil Aslan Güder sokak No:8
Beşiktaş, İstanbul 34349 Türkiye

Phone: +905332188868

Fax: +903124470963

Email: sedef.yenice@florence.com.tr; sedefyenice@gmail.com

Signature: 

Date: JUNE 27, 2025

3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues that you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

Commitment to Serve with Integrity and Vision

As an engaged leader and lifelong advocate for the advancement of laboratory medicine, I am honored to accept the nomination and submit my candidacy for Secretary of the IFCC Executive Board for the term 2027–2029. I am deeply committed to serving the IFCC and its global community with the integrity, rigor, and collaborative spirit that have guided my four decades in the field.

Ensuring Effective Governance and Communication

My vision as Secretary is to strengthen the Federation's operational excellence and responsiveness by ensuring that Executive Board decisions are effectively implemented, meetings and Council activities are well-organized, and communication with our Full and Affiliate Members is transparent, timely, and inclusive.

With proven leadership in institutional administration and management, international program development, and the creation of innovative projects in clinical laboratory medicine, education, and policy formation, I bring extensive experience coordinating large-scale and cross-cultural initiatives. I will dedicate my time and expertise to support the President and the Executive Board in realizing IFCC's strategic goals and promoting the mission of harmonizing laboratory practice worldwide.

Elevating Education and Accreditation Globally

A key priority will be to sustain and expand IFCC's educational and accreditation reach. As a founder of the EFLM CPECS® and major contributor to the IFCC PROCEED™ accreditation program, successfully registered as an official trademark under the European Union Intellectual Property Office (EUIPO), I have championed scalable systems that ensure continuing education remains rigorous, accessible, and internationally recognized.

I am committed to strengthening IFCC's CPD programs to benefit professionals everywhere, with special focus on emerging regions where capacity building is vital.

Supporting Continuous Quality Improvement in Developing Regions

As the IFCC National Representative for the Turkish Biochemical Society, I have recently submitted several proposals under the Foundation for Emerging Nations (FEN) initiative to advance Continuous Quality Improvement (CQI) in clinical laboratories within resource-limited settings. These projects aim to strengthen local laboratory capacity through targeted fellowships, regional workshops, a comprehensive e-learning course incorporating IFCC PROCEED™ accreditation for CE credits, and a Train-the-Trainer program designed to ensure lasting impact and multiplier effects. Each project is planned to be measurable, practical, and adaptable to diverse laboratory environments.

Driving Innovation, Collaboration, and Young Scientists' Engagement

I am determined to strengthen IFCC's role in driving innovation and fostering inclusive collaboration. My priorities include:

- **Empowering Young Scientists:** Actively supporting Young Scientists' projects and activities and promoting their integration within the Federation's structure to ensure that our next generation of laboratory professionals have the mentorship, recognition, and opportunities they need to shape the future of our discipline.
- **Integrating AI into Modern Laboratory Practice:** Promoting the responsible use of machine learning and decision support systems to advance evidence-based diagnostics.
- **Enhancing Data Quality Management and Governance:** Developing integrated frameworks for Data Quality Management (DQM) and Information Governance (IG) to improve data standards, patient safety, and quality of care.

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as Secretary. Font used should be Calibri; font size 11.

Leadership Across International Organizations

For over 12 years, I have held key leadership roles within the IFCC, EFLM, and CLSI, building structures that deliver measurable, lasting value. I currently serve as Chair of the IFCC Visiting Lecturer Program (VLP) and Executive Member of the IFCC Education and Management Division (EMD). I have chaired the IFCC Committee on Clinical Laboratory Management (C-CLM) and now contribute actively to the Committee on the Accreditation of Continuing Education (EBAccE), supporting the development of the IFCC PROCEED™ system and distance learning guidelines. During my C-CLM leadership, I coordinated 28 experts from 22 countries, delivering capacity-building programs and developing Clinical Laboratory Leadership Training Courses, and produced a guide on leadership basics. Under my leadership, the VLP expanded its reach significantly through lectures and workshops across diverse regions, with me delivering lectures and moderating workshops in 10+ VLP Invited Lecturer assignments under the IFCC VLP in various countries. As the current IFCC National Representative for the Turkish Biochemical Society, I continue to lead strategic projects.

Regional Service and Educational Leadership

At EFLM, I chair the Committee on Continuing Professional Education Crediting System (C-CPECS®), where I led the design and rollout of the CPECS®, expanding access to high-quality CPD across Europe. At CLSI, I contribute as an Expert Panel Member on Clinical Chemistry and Toxicology, authoring and editing multiple laboratory guidelines and short courses in laboratory best practices.

National Strategic Roles

Nationally, I have served as an advisor to the Turkish Ministry of Health on laboratory staffing plans, licensing, and national standards, and member of the Advisory Board of the Turkish Standards Institute. As a former Head and Founder of Clinical Laboratory Departments and Biochemistry Units, and as an Associate Dean responsible for curriculum development in a medical faculty, I have proven skills in strategic planning, education program design, and talent development.

Honors and Impact

My dedication has been recognized through awards such as the EFLM Academy Award, PFIZER International Pre-Clinical BPH Research Grant Award (Roerig/PFIZER Inc., USA), Dr. Praveen Sharma Oration, and the Asia-Pacific Federation for Clinical Biochemistry Appreciation Award, and national research honors, including “Eczacıbaşı” Award for Excellence in Medical Research and “National Scientific and Technical Research Council” (TÜBİTAK) Encouragement Award for Young Scientists. As an editorial board member and reviewer for leading international scientific journals, I champion quality and scientific rigor.

Commitment to Reliable Service

This record reflects my proven ability to coordinate diverse teams, manage complex projects, ensure diligent documentation, and maintain transparent communication, core duties of the Secretary.

5. Statement of Interests: *Please supply a statement of major professional, scientific, or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.*

Research and Academic Foundations

I began my career inspired by a precious scientific heritage from my mother, a dedicated clinical biochemist, and my father, a physician in internal medicine. Their commitment to patient care instilled in me a deep respect for the vital role of laboratory medicine (LM) in improving health outcomes. Building on this foundation, I trained as a research fellow and specialist in Medical Biochemistry and advanced my expertise through doctoral research in Cellular and Molecular Biochemistry and Pathology at the University of Minnesota (USA), focusing on prostatic cell growth and cancer biology. Postdoctoral studies at the University of Edinburgh (UK), supported by the European Urological Scholarship Foundation, along with training at Nagoya University School of Medicine, Research Institute for Disease Mechanism and Control, in Japan, broadened my perspective and strengthened my research skills. Early in my career, I was honored with 12 prestigious international fellowships from FEBS, EMBO, IUBMB, ICRO, and NATO, establishing a robust base for my enduring commitment to advancing LM.

Leadership in Quality and Accreditation

For over three decades, I have combined my scientific career with leadership in clinical laboratory management and education. As a Certified Expert in Hospital and Laboratory Accreditation (The Joint Commission, USA) and holding an Executive MBA from the Mendoza College of Business at the University of Notre Dame (USA), I have led continuous quality improvement (CQI) initiatives that have strengthened patient safety and service quality. Notably, I founded the Employees' Occupational Safety and Health Program (EOSH) across our hospital group, which was highlighted as a best-practice case in the Joint Commission's "Understanding Health Care Facility Safety".

Scientific Impact and Scholarly Contribution

I have authored 59 peer-reviewed publications, authored and contributed key book chapters, and my work has been referenced by over 1,139 academic papers on Academia.edu. My record also includes nearly 80 abstracts and proceedings.

Global Education and Capacity Building

As a strategic educator and program leader, I have designed and delivered over 20 major workshops through the IFCC, EFLM, ADLM (formerly AACC), and national societies. My lectures and training activities have reached professionals in more than 25 countries across five continents, strengthening practical skills in quality management, CQI, leadership, risk-based QC, and data-driven decision-making.

Commitment to Lifelong Learning and IFCC's Mission

Through my leadership in developing the EFLM CPECS® and contributing to the IFCC PROCEED™ accreditation framework, I remain deeply committed to expanding access to credible, structured continuing education worldwide. As IFCC Secretary, I will build on this foundation to champion global capacity, harmonized standards, and strong leadership, fully aligned with IFCC's mission to advance excellence in LM.



TBD

Turkish Biochemical Society

Hırfanlı Sokak 9/3 G.O.P. 06700 Ankara , Türkiye
Tel : +90 (312) 447 0997
Fax : +90 (312) 447 0963
E-mail: info@turkbiyokimyadermegi.org.tr
Web: <http://www.turkbiyokimyadermegi.org.tr>

President

Doğan YÜCEL, PhD, MedSp
Professor of Biochemistry
Lokman Hekim University Medical
Faculty Department of Medical
Biochemistry Ankara, TURKIYE
Tel: +90 (532) 354 2006
doyuysel@yahoo.com

Vice-President

Ferhan GİRGİN SAGIN, MD, PhD
Professor of Biochemistry Ege
University Medical Faculty
Department of Biochemistry Izmir,
TURKIYE
Tel: +90 (232) 390 4087
ferhan.sagin@gmail.com

General Secretary

Oğuzhan ZENGE, MedSp
Assoc. Professor of Biochemistry
Ministry of Health Istanbul Cam and
Sakura City Hospital Medical
Biochemistry Istanbul, TURKIYE
Tel: +90 (552) 424 7975
oguzhanzengi@gmail.com

Treasurer

Mehmet SENES, PhD, MedSp
Assoc. Professor
Ministry of Health Ankara Education
and Research Hospital Ankara,
TURKEY Tel: +90 (312) 595 3216
senesmehmet@yahoo.com

Members

Aylin Sepici DİNCEL, MD, MedSp
Professor of Biochemistry Gazi
University, School of Medicine Dept.
of Medical Biochemistry Ankara,
TURKIYE
Tel: +90 (312) 202 6934
asepicidinzel@gmail.com

Ali ÜNLÜ, MD, PhD

Professor of Biochemistry Selek
University Faculty of Medicine
Department of Biochemistry Konya,
TURKIYE Tel: +90 (332) 224 4799
aunlu@seluk.edu.tr

Muhittin A. Serdar, MD, MedSp

Professor of Biochemistry
Acibadem Mehmet Ali Aydınlar
University, Faculty of Medicine Dept.
of Medical Biochemistry Istanbul,
TURKIYE Clinlab Laboratories,
Ankara, TURKIYE
Tel: +90 (312) 472 3067
muhittin.serdar@acibadem.edu.tr

Günes Ozhan, PhD

Prof. of Molecular Biology and
Genetics Izmir Institute of
Technology Gulbağca Campus Izmir,
Research Group Leader Izmir
Biomedicine and Genome Center
Dokuz Eylül University Health
Campus, Izmir, TURKIYE Tel: +90
(232) 299 4156
gunes.ozhan@ibg.edu.tr

Serkan Bolat, MD, MedSp

Cumhuriyet University, Faculty of
Medicine Dept. of Medical
Biochemistry, Sivas, TURKIYE Tel:
+90 (507) 439 0028
drsbolat@gmail.com

June 28, 2025

To : Prof. Leslie Lai, IFCC IFCC Nominations Committee's Chair
From: Prof. Doğan Yücel, President of the Turkish Biochemical Society

Dear Prof. Lai,

On behalf of the Turkish Biochemical Society, I am pleased to formally nominate **Prof. Dr. Sedef Yenice** for the position of **Secretary of the IFCC Executive Board for the term 2027–2029**.

Prof. Yenice has demonstrated outstanding dedication and leadership in clinical laboratory science and international professional service. Her proven experience within IFCC, EFLM, and CLSI - as well as her contributions to education, accreditation, and global capacity-building initiatives - make her an ideal candidate for this important role.

The Turkish Biochemical Society fully supports her nomination and is confident that as the IFCC Secretary, she will bring valuable insight, organizational skill, and collaborative spirit to the IFCC Executive Board. We appreciate your consideration and extend our best wishes to all candidates.

Best regards,



Prof. Dr. Doğan Yücel
President
Turkish Biochemical Society



Zhen
ZHAO

**ASSOCIATION FOR DIAGNOSTICS &
LABORATORY MEDICINE (ADLM) - USA**



**NOMINATION FORM for SECRETARY
IFCC EXECUTIVE BOARD 2027-2029**

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of ...**Association for Diagnostics & Laboratory Medicine**.....
(insert name of National Society)

Name:.....Mark J. Golden.....

Office held within the National Society:National Representative to the IFCC Council..
(This should normally be the nominated National Representative to the IFCC Council)

We nominate for the Office of Secretary for the term 2027-2029

.....Zhen Zhao.....
(insert name of nominee)



Signature:.....

Date:6/11/2025.....

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I,Zhen Zhao.....
(insert name)

accept nomination for election to the position of Secretary.

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address:1300 York Avenue, F701, New York, NY 10065, USA
.....

Phone:212-746-2682.....

Fax:

Email: zhz9010@med.cornell.edu.....

Signature:..... Date:.....4/23/2025.....

3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues which you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

It is with great commitment and enthusiasm that I am being considered for nomination as Secretary of the IFCC Executive Board for the 2027–2029 term. I bring to this role a wealth of experience in academic leadership, clinical operations, international health collaboration, and interdisciplinary research—reflecting the diversity and dynamism of IFCC’s global membership.

As the IFCC continues to expand its global footprint, several key challenges lie ahead: strengthening coordination across scientific divisions, improving the visibility of laboratory medicine’s impact on patient outcomes, and building administrative systems that support transparency, agility, and global engagement. These are areas where I believe the Secretary can play a strategic role—not only in execution, but also in shaping process and structure.

In my current role as Professor of Clinical Pathology and Laboratory Medicine at Weill Cornell Medicine and Director of the Central Laboratory at NewYork-Presbyterian/Weill Cornell, I lead diagnostic services across multiple care settings and oversee an annual test volume of over 18 million. As part of our enterprise-wide strategy, I have spearheaded laboratory standardization across eight hospitals—aligning laboratory practices, test utilization, and informatics infrastructure to optimize quality and efficiency. These initiatives exemplify the kind of organizational discipline, stakeholder coordination, and systems-level thinking that are vital to the Secretary’s role in supporting IFCC’s complex and evolving structure.

Internationally, I have served as Chair of the IFCC Task Force on Outcome Studies in Laboratory Medicine (TF-OSLM) since 2021. We established the first global database capturing the clinical impact of diagnostics and created a competitive funding mechanism to seed outcome studies worldwide. I also contributed to IFCC’s collaborations with the WHO, including the Model List of Essential In Vitro Diagnostics, the IFCC–WHO Collaboration Plan, and the WHO Global Diagnostics Coalition. These efforts reflect my ongoing commitment to strengthening IFCC’s leadership at the intersection of science, policy, and implementation.

Throughout my career, I have collaborated extensively with clinical teams, academic researchers, engineers, and industry leaders to develop and validate cutting-edge diagnostics. This cross-sector approach enables me to understand the needs and perspectives of IFCC’s multidisciplinary membership. As IFCC continues to expand its reach and relevance, fostering inclusivity and cross-functional communication will be essential to ensuring alignment with the organization’s goals.

I have authored over 100 peer-reviewed publications, including in *Nature*, *Cell*, *JCI*, *JAMA Network Open*, *Clinical Chemistry*, and *PNAS*, and currently serve on editorial boards for several leading journals. I was honored to receive the 2024 IFCC Distinguished Woman Scientist Award for Contributions to In Vitro Diagnostics—a recognition of both scientific achievement and commitment to the global diagnostic community.

If elected Secretary, I will focus on enhancing communication infrastructure, fostering productive alignment across committees and divisions, and ensuring that IFCC’s internal systems reflect the clarity, transparency, and professionalism needed to support its strategic growth. It would be a privilege to serve the IFCC community in this capacity.

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as Secretary. Font used should be Calibri; font size 11.

Over the past decade, I have demonstrated sustained commitment to IFCC's mission through leadership roles, collaborative initiatives, and strategic contributions. As Chair of the IFCC Task Force on Outcome Studies in Laboratory Medicine (TF-OSLM), I led the design and launch of the first global outcome study database for laboratory testing. In addition, we established a funding program to support new outcome-focused studies worldwide—offering mentorship, peer-review support, and seed grants to advance IFCC's vision of data-driven diagnostics.

This work required cross-functional engagement, coordination with investigators across multiple continents, and alignment with IFCC strategic goals. The operational infrastructure and documentation that underpinned this initiative align directly with the core responsibilities of the Secretary role. The success of the TF-OSLM has also positioned IFCC as a leader in articulating the clinical impact of diagnostics—a priority that I believe the Board must continue to elevate.

In addition to task force leadership, I have served as a representative in several key IFCC–WHO collaborations, including participation in the WHO Global Diagnostics Coalition and contribution to the WHO Model List of Essential In Vitro Diagnostics. These roles involved representing IFCC in multisector, policy-driven discussions and highlighted the importance of structured documentation and inter-organizational coordination.

I also bring national and regional governance experience through my leadership in the Association for Diagnostics & Laboratory Medicine (ADLM), where I currently serve as President-Elect of the ADLM Academy. My previous roles include Chair of the Clinical Translational Science Division, Chair of the Tumor Markers and Cancer Diagnostics Division, and Poster Abstract Coordinator for the ADLM Annual Meeting. I also served as Past President of the North American Chinese Clinical Chemists Association (NACCCA).

In my institutional role, I led a laboratory unification strategy across eight affiliated hospitals in the NewYork-Presbyterian network—an effort that demanded operational precision, collaborative leadership, and robust documentation practices.

Collectively, these experiences reflect my readiness to support IFCC through the critical administrative and strategic responsibilities of the Secretary role.

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

My research interests center on diagnostic innovation, translational assay development, and the integration of laboratory medicine into patient-centered care pathways. I lead a dynamic research program that leverages clinical chemistry, biomedical engineering, and machine learning to develop ultrasensitive diagnostic platforms and clinically relevant biomarkers.

Our lab has pioneered biosensor-based diagnostics for SARS-CoV-2, creating multiplexed assays to assess total, neutralizing, and avidity-based antibody responses. These platforms were among the first to be clinically implemented during the COVID-19 pandemic, providing real-time data to guide clinical decisions and public health responses. Our studies on pediatric antibody responses and immune profiling of convalescent individuals were published in *JAMA Network Open*, *JCI Insight*, and *Clinical Chemistry*, and have influenced policy at both institutional and national levels.

We have also developed CRISPR- and nanoparticle-enhanced assays to detect tuberculosis antigens, cancer biomarkers, and circulating DNA fragments in blood. These tools address diagnostic gaps in low-resource and time-sensitive settings, aligning with IFCC's commitment to global diagnostic equity.

Beyond infectious diseases, my team has identified novel exosome and microRNA biomarkers for early detection of conditions such as cervical cancer, ectopic pregnancy, and chronic lymphocytic leukemia. We have published in high-profile journals including *Nature*, *Nature Biomedical Engineering*, *Cell*, and *PNAS*, reflecting the translational scope and scientific impact of our work.

Importantly, these projects are driven by a multidisciplinary framework. I collaborate with engineers to design novel sensor technologies, with clinicians to validate diagnostic utility in real-world settings, and with industry partners to support commercialization and scale-up. This cross-sector engagement reflects the diversity of IFCC's membership and ensures that our solutions are both innovative and implementable.

As associate editor of *Annals of Medicine* and several other journals, I remain actively engaged in evaluating global diagnostic research and shaping emerging trends in laboratory science. My work is grounded in a belief that laboratory medicine is essential not only for diagnosis, but also for improving patient outcomes.

If elected Secretary, I will bring these perspectives—grounded in innovation, scientific rigor, and global implementation—to help IFCC advance diagnostic excellence, promote outcome-driven testing strategies, and foster equitable access to laboratory services worldwide.



June 10, 2025

Prof. Leslie Lai
Chair
IFCC Nominations Committee's Chair
IFCC

RE: ADLM's Nomination of Dr. Zhen Zhao, Ph.D. for the Position of Secretary of the IFCC

Dear Prof. Lai:

As the National Representative to the IFCC Council, I am pleased to inform you that the ADLM is nominating Dr. Zhen Zhao, Ph.D. for the position of IFCC Secretary, on the basis of her extensive service to ADLM and the broader field of laboratory medicine.

After receiving her Ph.D. in Neurobiology and Physiology from Northwestern University, Dr. Zhao completed both clinical chemistry and postdoctoral fellowships at Washington University in St. Louis School of Medicine. In addition to her extensive laboratory and hospital experience, Dr. Zhao has held academic appointments in leading institutions, such as the prestigious Weill Cornell Medicine, where she serves as Professor of Clinical Pathology and Laboratory Medicine.

Dr. Zhao has held several roles in ADLM and the ADLM Academy.

If you have any questions, you may contact me directly or Kerry Cosby (kcosby@myadlm.org), Director of Global Affairs.

Sincerely yours,



Mark J. Golden
Chief Executive Officer



IFCC

*International Federation
of Clinical Chemistry
and Laboratory Medicine*

Nominations for TREASURER

2027 - 2029

CANDIDATES

Nominees

Company

Sergio
BERNARDINI

Italian Society of Clinical
Biochemistry and Clinical
Molecular Biology – Laboratory
Medicine (SIBioC) – Italy

Mariam
KLOUCHE

Deutsche Gesellschaft
für Klinische Chemie und
Laboratoriumsmedizin /
German Society for Clinical
Chemistry and Laboratory
Medicine (DGKL) - Germany



Sergio BERNARDINI

ITALIAN SOCIETY OF CLINICAL BIOCHEMISTRY AND CLINICAL MOLECULAR BIOLOGY - LABORATORY MEDICINE (SIBIOC) - ITALY



NOMINATION FORM for TREASURER IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of the Italian Society of Clinical Biochemistry and Laboratory Medicine (SIBioC)
(insert name of National Society)

Name: Prof. Marcello Ciaccio

Office held within the National Society: President
(This should normally be the nominated National Representative to the IFCC Council)

We nominate for the Office of Treasurer for the term 2027-2029

Prof. Sergio Bernardini
(insert name of nominee)

Signature: *Marcello Ciaccio*

Date: *March 31st 2025*

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

Sergio Bernardini
(insert name)

accept nomination for election to the position of Treasurer.

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: Viale Tito Labieno 122, 00174 Rome, Italy

Phone: +39 3804399292

Fax:

Email: sbernardini.med@gmail.com

Signature: *Sergio Bernardini*

Date: April 2nd, 2025

3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues which you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

The International Federation Clinical Chemistry and Laboratory Medicine celebrated its 70th anniversary three years ago and continues to be the leading organization of Laboratory Medicine in the world. In fact, the growth of the IFCC continues and currently about 100 Countries are full members and 20 affiliate members with over 1000 professionals and scientists involved in its functional units that have exceeded the number of 60.

Standardization/harmonization of laboratory procedures, organization and management of the clinical laboratory, the Value of Laboratory Medicine, Communication and Educational activities are just some of the many fields of activity of committees, working groups and task forces.

The IFCC has a proactive presence at a global level and therefore the role of the IFCC is also to contextualize the initiatives in the different Countries taking into account the local needs and opportunities.

This is a very important challenge that only a deep knowledge of the IFCC structure and the multi-year experience of activities carried out all over the world can allow to face.

Furthermore, technological development in Laboratory Medicine is much faster than new practical applications especially in low and middle incomes countries.

The role of the IFCC is therefore to implement equity of resources and opportunities among its members and in this issue the treasurer could have a strategic role.

In this context, the IFCC should also implement relationships with national institutions through its members and with supranational institutions in order to increase the impact of initiatives such as the support for neonatal screening or the prevention of non-communicable diseases.

A new role that goes beyond educational and standardization activities and could have a significant impact on the lives of citizens worldwide.

These new activities would require additional resources to those in place and therefore a fundraising strategy that the treasurer could implement together with the Executive Board and the functional units.

Then IFCC should be active not only for professionals in Laboratory Medicine but above all for citizens and patients.

This implies a review of the format of the conferences in which patient associations and professionals from clinical and others diagnostic sciences should participate, considering that only integrated diagnostics can determine a real change in healthcare processes. In this case my experience as Chair of the Emerging Technologies Division of the IFCC and as director of an Integrated Diagnostics Department in the University Hospital in Rome could be very useful.

Finally, my experience in the Finance Committee of the current Executive Board combined with the knowledge acquired during the Master in Health Economics and Management could be important in communicating with the financial structures to which the IFCC turns to manage its assets but also for the organization of its activities and Congresses.

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as Treasurer. Font used should be Calibri; font size 11.

I was Past President of the Italian Society Laboratory Medicine (SIBioC) and SIBioC Representative in IFCC since many years.

I served IFCC in the position of Executive Board Secretary for a first term since 2012 to 2014 (President Prof. Graham Beastall), and for a second term since 2015 to 2017 (President Prof. Maurizio Ferrari).

During the second term I contributed to the creation of the Emerging Technologies Division (ETD) of IFCC and I was the Chair of this Division since 2018 to 2023.

To date I'am Executive Board Secretary for the term 2024-2026 (President Prof. Tomris Ozben).

I had been the President of the 25th WorldLab/EuroMedLab held in Rome in May 2023.

Moreover I organized many others IFCC Conferences worldwide about neurodegenerative diseases (Toronto and Mexico City), Point of Care Testing (Rome) and the first Conference of Mediterranean Laboratory Medicine in Rome in 2018.

The work done during 14 years of Service has allowed to realize an in-depth knowledge of the structure of the IFCC, of the Office, of all its functional units and of their management which could be very important in the role of treasurer at the service of the executive board and the officers of the IFCC.

Moreover in 2021 I got a 2nd Level Master in Health Economy and Managements that for sure would be useful in the role of treasurer from the technical point of view.

This is way I'd like continue serving IFCC in this very important role contributing to maintain efficiency, equality and transparency in the management of IFCC finances.

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

I'm Medical Doctor since almost 40 years and postgraduate in Paediatrics and Laboratory Medicine and then PhD. Since 20 years I'm full professor in Clinical Biochemistry and Clinical Molecular Biochemistry at the University of Tor Vergata in Rome. I had been Dean of the Degree Courses in Laboratory Technologists and Pharmacy and Director of the post graduate School in Clinical Pathology of the same University.

I'm teaching Laboratory Medicine at the Degree Course in Medicine of my University since 1998.

I had been Head Physician of the Laboratory Medicine Unit of the University Hospital of Tor Vergata in Rome since 2008.

To date I'm Director of the Integrated Diagnostics Department of the University Hospital of Tor Vergata which includes Clinical Biochemistry, Microbiology, Pathology, Blood Bank and Radiology.

During my career I published almost 400 papers in peer reviewed International Journals reaching 57 H-Index and almost 14.000 citations.

My main fields of interest in Research during my career have been cancer, neurodegenerative diseases and emerging technologies.

I hope that these professional and academic activities can contribute to have a supporting role at the mission of IFCC in terms of Education, Communication and Science.

SIBioC

Medicina di Laboratorio ETS

Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica ETS
membro dell'European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
e International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)

CONSIGLIO DIRETTIVO

PRESIDENTE

Marcello Ciaccio (Palermo)

PAST PRESIDENT

Tommaso Trenti (Modena)

VICE PRESIDENTE

Sabrina Buoro (Milano)

SEGRETARIO-TESORIERE

Antonio Fortunato (Ascoli Piceno)

CONSIGLIERI

Anna Carobene (Milano)

Davide Giarina (Vicenza)

Bruna Lo Sasso (Palermo)

Rita Mancini (Bologna)

Roberta Rolla (Novara)

Stefano Angelo Santini (Roma)

Matteo Vidali (Milano)

Eustachio Vitullo (Matera)

RAPPRESENTANTI

DIVISIONE TECNICO PROFESSIONALE

Davide Farci Santarcangeli (Milano)

Mario Mela (Modena)

Milan, May 28th, 2025

Dear International Federation of Clinical Chemistry,

I am attaching a format for the candidature of Professor Sergio Bernardini
as Treasurer of the IFCC.

Kind regards,

Marcello Ciaccio

Prof. Marcello Ciaccio

President, SIBioC - Laboratory Medicine



Mariam KLOUCHE

**DEUTSCHE GESELLSCHAFT
FÜR KLINISCHE CHEMIE UND
LABORATORIUMSMEDIZIN
(DGKL) - GERMANY**



NOMINATION FORM for TREASURER IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of DGKL Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin,
Germany
(insert name of National Society)

Name: Prof. Dr. med. Harald Renz

Office held within the National Society: President of the DGKL
(This should normally be the nominated National Representative to the IFCC Council)

We nominate for the Office of Treasurer for the term 2027-2029

Prof. Dr. med. Mariam Klouche, Vice-President of the DGKL
(insert name of nominee)

Signature: 

Date: 26.06.2025

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

Prof. Dr. med. Mariam Klouche

accept nomination for election to the position of Treasurer.
and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: LADR Laborzentrum Bremen
Friedrich-Karl-Strasse 22
28205 Bremen
Germany

Phone: +49 421 4307233

Fax: +49 421 4307235

Email: mariam.klouche@laborzentrum-bremen.de

Signature:  Date: 26.06.2025

3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues which you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

Prof. Dr. med. Mariam Klouche

I am currently Vice-President (President-Elect) of the German Society for Laboratory Medicine and Clinical Chemistry (DGKL), where I have served on the Board for the past seven years. My involvement with IFCC dates back to 2003 and includes active participation in committees and working groups focusing on education, management, and public relations (C-ECD, C-PR). I also coordinated the European Labtestsonline Editors Group in association with IFCC for more than 15 years.

As an international organization representing over 100 countries, the IFCC plays a vital role in advancing laboratory medicine worldwide. The IFCC requires strong and reliable financial governance, transparency, strategic foresight, long term planning and efficient day-to-day management of its finances to fulfill its mission and global impact.

1. Shaping IFCC's Financial Vision and Stability

IFCC's global leadership depends on a solid financial foundation and structure. As Treasurer, I am committed to ensuring sustainable operational capacity through meticulous budget planning, careful financial management, and proactive oversight. My role will include managing the operational budget, overseeing the investment portfolio, ensuring timely reimbursements, and providing financial guidance to the Executive Board and member societies. Strengthening IFCC's financial resilience will help sustain innovation, education, and research, even in times of economic constraint.

2. Upholding the responsibilities and integrity of the Treasurer

A treasurer in a global scientific organization must combine technical financial acumen with reliability, independence, and transparency. Given IFCC's status under Swiss law and its banking structure based in Switzerland, strict adherence to international nonprofit financial standards is essential. I will ensure compliance with all applicable legal and regulatory requirements, maintain accurate and auditable records, and protect IFCC's assets with the utmost integrity and diligence.

3. Strengthening and expanding IFCC's funding base

One of my key objectives will be to stabilize and further develop IFCC's financial base by deepening relationships with long-term IVD partners, attracting new industry partners (including from biotech, IT, AI sectors), and engaging external stakeholders who align with IFCC's mission. I will also promote the IFCC Board's activities to expand its global network beyond its current base.

4. Risk assessment, compliance and foresight

Drawing on my experience as CEO and treasurer in regional non-profit medical societies, I will implement foresighted risk assessment practices to anticipate potential legal and financial challenges. Ensuring compliance with evolving international regulatory frameworks is essential for safeguarding IFCC's operations and its non-profit status.

5. A global perspective on public health and development

Throughout my career, I have promoted global health initiatives, working with multidisciplinary and multicultural teams across various levels of healthcare systems. I will contribute to enhancing IFCC's collaboration with global health institutions such as WHO, UN agencies, OECD, ECDC. These partnerships will support the execution of IFCC-backed projects worldwide and further IFCC's commitment to global health equity.

As IFCC Treasurer, I will bring financial expertise, a strategic vision, and a deep commitment to the mission of IFCC. I offer my candidacy in a spirit of integrity, transparency, and international solidarity, with a strong dedication to serving the IFCC members across the globe.

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as Treasurer. Font used should be Calibri; font size 11.

Prof. Dr. med. Mariam Klouche

Since 2003, I have served in various IFCC Divisions and Committees, including the Education and Management Division, the C-ECD Committee on Education and Curriculum Development, and the Distant Learning Working Group, where I helped develop educational resources for global dissemination. I also contributed to the C-PR Public Relations Committee and led the European Labtestsonline Editors Network for over 17 years. Additionally, I supported the IFCC "Labs Are Vital" program in partnership with Abbott Diagnostics.

For the past seven years, I have served on the Board of the German Society of Laboratory Medicine and Clinical Chemistry (DGKL), currently as Vice-President. During this time, I represented Germany as National Representative to both IFCC and EFLM, strengthening international engagement and communication.

My experience extends to major scientific and regulatory organizations. For over two decades, I have served on the Advisory Committee of the German Reference Institute for Bio-analytics, a key provider of global EQC services, the last 7 years also on its board. I also sit on the Board of the Foundation of Patho-biochemistry and Molecular Biology, supporting educational initiatives for young scientists. These roles have equipped me with deep financial, structural, and legal knowledge in managing scientific trusts and non-profit foundations—skills essential for the IFCC Treasurer's responsibilities.

In the public sector, I have held prominent positions, including appointment by the German Ministry of Health to the first Expert Commission on the Genetic Diagnostics Law, where I have served as Co-Chair for the past six years. I was also appointed to the Accreditation Council of the German Ministry for Economic Affairs and Energy. I organized the Franco-German Health Forum in Paris, attended by both countries' health ministers, and have fostered strong European collaboration.

As a member of the Académie Nationale de Pharmacie (France), I have been deeply engaged in international Francophone cooperation in laboratory medicine, organizing congresses and serving as President of the International Committee of the Journées de l'Innovation (JIB) for several years.

Through these extensive networks, I have consistently advocated for the central role of laboratory medicine in public health. My experience managing financial and regulatory matters, particularly in complex and multidisciplinary environments, demonstrates the diligence, strategic vision, and integrity I will bring to the role of IFCC Treasurer.

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

Prof. Dr. med. Mariam Klouche

Contributing to global prevention of diseases and promoting access to accurate diagnosis is my core professional interest.

1. Special expertise in laboratory management and organisation of scalable labs

Organising laboratories adapted to the needs and premises of affluent and low-income countries is a mainstay of my work. Regarding complex laboratories, I established a new centre for stem cell transplantation and advanced cellular and genetic therapies as Professor at Regensburg University. With a fundamental change in medical law in Germany in 2004, I had the chance to design the first public-private transsectoral comprehensive laboratory covering four teaching hospitals and several hundred ambulatory centres. I developed practical concepts for smaller hospitals and POCT solutions for remote areas and migrant reception centres. My expertise as Medical Director and CEO for the last 20 years with responsibility of an annual volume of 18-20 Mio. EUR, ensures accurate financial management for the responsibility as IFCC treasurer.

2. Support IFCC education & professional development and promote counselling guidance

To advance outreach of laboratory diagnosis for better patient care, I established several regular co-educational formats for laboratory specialists and clinicians. Most recently, the annual "DGKL-Kolleg" for the training of counselling competence. As Professor for Laboratory Medicine I teach medical students, and also master-students of biometrics (biologists, chemists, engineers). Besides internet-based teaching, I have contributed to textbooks of laboratory medicine, e.g. "Das Laborbuch für Klinik und Praxis", "Molecular and Cellular Biology", "Cellular Analysis and Therapy", and performed translations into German, e.g. "Harrisons Principles of Internal Medicine" to promote accessibility.

3. Broadening the scope of IFCC by connecting with other diagnostic disciplines

Being a triple specialist for laboratory medicine, medical microbiology and transfusion medicine, I organise regular diagnostic discipline overarching symposia for medical doctors, laboratory specialists and medical technologists, contributing to intensify dialogue. My postgraduate training activities create an average of 280 CME credit points annually.

4. Advocacy for IFCC by strengthening collaboration with WHO and other stakeholders in health

By collaboration with different stakeholders including GTZ, WHO, Institut Pasteur Rabat, Morocco, I have conducted projects in West-Africa (1995-2000), initiated a lecture-series on "Santé globale: diagnostique sans frontières" and "Santé mondiale: prévention sans frontières" (1998-2004). I was visiting professor in Damaskus, Syria in 2010-2011. My research on inflammatory pathogenesis of atherosclerosis and on vironines in AIDS, was awarded the Gotthard Schettler Price, the Atherosclerosis Society Price and the Exceptional AIDS Price, also addressed my professional Leitmotif improving global health.

Das Präsidium



DGKL-Geschäftsstellen
Friesdorfer Str. 153 | 53175 Bonn
Alt-Moabit 96a | 10559 Berlin

Präsident
Univ.-Prof. Dr. H. Renz

Vizepräsidentin
Prof. Dr. M. Klouche

Schatzmeister
Prof. Dr. M.F. Bauer, MBA

Schriftführerin
Prof. Dr. J. Schanz

Präsidiumsmitglied
Prof. Dr. U. Ceglarek

Präsidiumsmitglied
Prof. Dr. T. Streichert

Past-Präsident
Univ.-Prof. Dr. M. Nauck

Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin
Geschäftsstelle | Alt-Moabit 96a | 10559 Berlin

IFCC Nominations Committee

Nomination of Prof. Dr. Mariam Klouche as Treasurer of IFCC

19.06.2025

Dear IFCC Nominations Committee Chair Professor Lai,

the Executive Board of the German Society of Clinical Chemistry and Laboratory Medicine (DGKL) is proud and honored to nominate our highly respected colleague Prof. Dr. Mariam Klouche as candidate for the position as the IFCC treasurer for 2027-2029.

Prof. Klouche is absolutely reliable and credible colleague. She has been re-elected as Vice President and is a valued member of the board she since seven years. She is engaged for 25 years in our national society DGKL and she contributed tremendously to advance laboratory medicine taking the lead in establishing and promoting national and international educational programs, distance learning and interdisciplinary postgraduate training. As Professor she is dedicated to strengthen broad professional development, she teaches medical students, and also biologists, chemists and engineers for a bachelor and master in medical biometry.

As Medical Director she has established and is responsible for the first public-private partnership comprehensive laboratory covering several teaching hospitals and ambulatory practices. Being a triple specialist for laboratory medicine, medical microbiology and transfusion medicine, she is very well connected in different diagnostic disciplines worldwide.

She consistently represents laboratory medicine and quality assurance in multiple governmental organizations also in the Advisory Board of the Federal Medical Chamber.

Prof. Klouche has vast experience in all financial, legal and organizational aspects required for the treasurer of IFCC. We enjoy working with her in the Board of DGKL and highly estimate her cooperative leadership and strong determination to advance our profession. We are convinced that Prof. Mariam Klouche will contribute in multiple ways to the success of IFCC and that she will be a most reliable treasurer.



Prof. Dr. Harald Renz
President of the DGKL

Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin e. V.

Kontakt
Tel.: 0228 92 68 95-0 (Bonn)
Tel.: 030 39 40 54-16 (Berlin)
E-Mail: geschaeftsstelle@dgkl.de

Bankverbindung
BBBank Karlsruhe
BIC: GENODE61BBB
IBAN: DE35 6609 0800 0017 4583 47

Steuernummer
206/5887/1282
Umsatzsteuer-IdNr.
DE 231 466 924

Vereinsregister
HRB VR12527
Amtsgericht Frankfurt am Main
www.dgkl.de



IFCC

*International Federation
of Clinical Chemistry
and Laboratory Medicine*

**REGIONAL
FEDERATIONS
Representatives
Nominations
2027 - 2029**

LIST OF CANDIDATES

Nominees	Regional Federation
<p>Rajiv ERASMUS</p> <p>Nominated by: South African Association for Clinical Biochemistry and Laboratory Medicine (SAACB)</p>	<p>African Federation of Clinical Chemistry (AFCC)</p> 
<p>Myrna GERMANOS</p> <p>Nominated by: Lebanese Society of Clinical Biology/ Syndicat des Biologistes du Liban (SDBLB)</p>	<p>Arab Federation of Clinical Biology (AFCB)</p> 
<p>Samuel VASIKARAN</p> <p>Nominated by: Australasian Association for Clinical Biochemistry and Laboratory Medicine (AACB)</p>	<p>Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB)</p>  <p>ASIA-PACIFIC FEDERATION FOR CLINICAL BIOCHEMISTRY AND LABORATORY MEDICINE</p>
<p>Tomas ZIMA</p> <p>Nominated by: Czech Society of Clinical Biochemistry (CSKB)</p>	<p>European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)</p>  <p>EUROPEAN FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE</p>
<p>Eduardo FREGGIARO</p> <p>Nominated by: Confederación Unificada Bioquímica de la República Argentina (CUBRA)</p>	<p>Latin-American Confederation of Clinical Biochemistry (COLABIOCLI)</p>  <p>COLABIOCLI</p>
<p>Carmen Elizabet TROCHE CABALLERO</p> <p>Nominated by: Asociación de Bioquímicos del Paraguay (ABP)</p>	<p>North American Federation of Clinical Chemistry and Laboratory Medicine (NAFCC)</p>  <p>NAFCC North American Federation of Clinical Chemistry & Laboratory Medicine</p>
<p>To be nominated</p>	 <p>NAFCC North American Federation of Clinical Chemistry & Laboratory Medicine</p>



Myrna GERMANOS

**LEBANESE SOCIETY OF CLINICAL
BIOLOGY / SYNDICAT DES BIOLOGISTES
DU LIBAN (SDBLB) - LEBANON**



NOMINATION FORM for REGIONAL FEDERATION REPRESENTATIVE IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of The **Syndicate of Clinical Biologists of Lebanon (SCBL)**

Name: **Christian HADDAD**

Office held within the National Society: **SCBL Executive Board member**
(This should normally be the nominated National Representative to the IFCC Council)

We nominate for the Office of the Arab Federation of Clinical Biology (AFCB)

Dr Myrna GERMANOS, President of the Syndicate of Clinical Biologists of Lebanon

Signature:

Date: June 26th 2025

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, **Myrna GERMANOS HADDAD, Clinical Biologist**

Accept nomination for election to the position of the **Arab Federation of Clinical Biology (AFCB)**
Regional Federation Representative,
and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: **Lebanese Order of Physicians LOP, Beirut, Lebanon**
Phone: **+961(0)3344760**
Fax: **+961(0)1294101**
Email: **myrnagermanos2@hotmail.com**

Signature:

Date: June 26th 2025

3. Statement of Intent

I am writing to express my sincere interest and great honor in being considered as the official candidate of the Arab Federation of Clinical Biology (AFCB) for the upcoming elections to the Executive Board of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). As a passionate clinical biologist and **President of the Syndicate of Clinical Biologists of Lebanon (SCBL)**, I have dedicated my career to the advancement of laboratory medicine, both in Lebanon and across the Arab region. I have always believed in the power of international collaboration and scientific exchange in shaping the future of our profession. Over the years, I have actively led the organization of congresses, continuing education programs, and scientific initiatives, all aimed at strengthening networks between professionals, academic institutions, and the diagnostics industry. These experiences have provided me with valuable insight into the global landscape of laboratory medicine and a strong understanding of IFCC's structure, mission, and strategic priorities. Beyond academic and organizational efforts, I am deeply committed to **mentoring young professionals**, fostering a **culture of quality and ethics** in laboratory practice, and **promoting inclusive cooperation across national and institutional boundaries**. I take pride in being a team-oriented leader, a strategic thinker, and a passionate advocate for excellence in our field. If elected to the IFCC Executive Board, I will bring this experience and dedication to serve the global community. My goals will include: Promoting **capacity-building and mentorship** in underserved countries, particularly within the Arab region, enhancing **youth engagement** through scholarships, virtual exchanges, and regional networks for young scientists, fostering **inclusive and evidence-based collaboration** between North and South, creating sustainable models of **knowledge-sharing**, supporting **digital transformation** by promoting equitable access to innovation and technology. I would be honored to bring my experience and dedication to the IFCC Board, where I would strive to represent the interests and strengths of our Arab region while **contributing to the Federation's global mission**.

4. Statement of Interests

My major professional interests have consistently centered on four key pillars: **laboratory accreditation, continuing education, quality control, and rare bleeding disorders**. I have worked extensively on **implementing laboratory accreditation in Lebanon** based on official national programs. To this end, I have completed advanced training at the Ministry of Public Health and the École Supérieure des Affaires, and contributed directly to **drafting national guidelines and policies**. I have also strongly **promoted continuing education for biologists and young scientists**, through structured training programs and collaborative knowledge-sharing platforms. In the absence of a national external quality assessment program, I **initiated quality control schemes in biochemistry, microbiology, and hematology** with the support of expert groups from France, improving result reliability and laboratory standards nationwide. **Teaching is central to my mission**. I currently teach immunology and hematology at Saint Joseph University of Beirut in both the medical and pharmacy faculties, as well as at the University of the Holy Spirit of Kaslik USEK. I have mentored generations of students and supervised hundreds of laboratory trainees during my long clinical career at Hôtel-Dieu de France hospital. I have also been deeply involved in the diagnosis and care of patients with rare bleeding disorders. Working closely with international experts, I helped establish a **national database** of local cases and contributed to collaborative research in this field. In parallel, I have worked with non-governmental organizations **to improve access to treatment and training** for both healthcare professionals and patients. This includes developing support networks to ensure individualized management plans for each patient and strengthening education on rare coagulation disorders. During the **COVID-19 pandemic**, I was officially assigned to coordinate the **nationwide organization of PCR laboratories**. Under my leadership, 110 fully operational molecular biology labs were implemented across Lebanon, many in facilities with no previous molecular diagnostics capabilities. As a result of my studies in microbiology at the **Institut Pasteur in Paris**, I have maintained a strong interest in **epidemiology** and have conducted numerous nationwide investigations throughout my hospital career. Since 1997, I have organized **annual national and international congresses in clinical biology** and remain actively engaged in **biomedical ethics**. I am regularly consulted by the Lebanese Order of Pharmacists and the Ministry of Health on sensitive ethical issues. My commitment to equity in healthcare drives my efforts to promote **access to knowledge and diagnostics in underserved regions, both locally and internationally**.

5. Statement of Service

It is with great honor and deep professional commitment that I submit this nomination, which reflects my enduring dedication to the advancement of clinical biology and laboratory medicine across local, regional, and international levels.

Since 2019, I have had the privilege of serving as **President of the Syndicate of Clinical Biologists of Lebanon (SCBL)**, after having been an active member of its **Executive Board since 2016** and **President of its Scientific Committee since 2010**. Through these roles, I have led strategic initiatives to strengthen the profession, enhance continuing education, and support the role of biologists as integral stakeholders in patient care, diagnostics, and public health policy. I served as **Head of the Hematology and Immunology Laboratories** at Hôtel-Dieu de France in Beirut during which I trained generations of young scientists

Beyond the syndicate, I am a founding member and current Executive Board member of the **Lebanese Consumer Protection Society**, through which I have actively contributed to national health advocacy and the defense of patient rights. I **also founded the Lebanese Committee on Hemostasis and Thrombosis** and am an engaged member of the Lebanese **Hemophilia Society**. In the realm of laboratory regulation and quality assurance, I currently **preside over the National Laboratory Accreditation Committee and the Laboratory Authorization Committee established for the national SARS-CoV-2 response**. Additionally, I lead the **Commission for Laboratory Organization within the Lebanese Order of Pharmacists**, working to ensure compliance, modernization, and excellence across the sector.

My contributions also extend to health system governance, particularly as a member of the **Assembly of Lebanese Health Orders**, where I support capacity building and human resource development across the healthcare system. Recognizing the importance of nurturing the next generation of scientists, I **founded both the Lebanese and Arab Young Scientists Groups**, providing platforms for emerging professionals to connect, innovate, and grow. On the international level, I serve as **vice- President of the International Francophone Federation of Clinical Biology and Laboratory Medicine (FIFBCML)**, **Co-President of the Scientific Committee of the Arab Federation of Clinical Biology (AFCB)**. I am an active member of the **Lebanese Epidemiology Association**,

And last but not least I am proud to be **member of the IFCC Nominations Committee**.

These roles reflect my commitment to global collaboration and knowledge exchange.

Finally, I am also deeply engaged in various **charitable initiatives focused on improving healthcare** access and outcomes for underserved populations. This nomination underscores my lifelong mission to elevate laboratory medicine, champion scientific leadership, and promote collaborative, patient-centered healthcare system

Syndicat des Biologistes du Liban

Membre de La Fédération Internationale
De Chimie Clinique (IFCC)
Membre de la Fédération Arabe
De Biologie Clinique (AFCB)
Membre de La Fédération Internationale
Francophone de Biologie Clinique et
Médecine de Laboratoire (FIFBCML)



نقابة أصحاب المختبرات الطبية في لبنان

عضو الاتحاد الدولي للكيمياء السريرية
عضو الاتحاد العربي للبيولوجيا السريرية
عضو الاتحاد الدولي الفرنتكوفوني للبيولوجيا السريرية

Lebanese Syndicate of Clinical Biologists (SDBL)

Beirut, Lebanon
June 26th 2025

To Whom It May Concern,

Subject: **Letter of Support for Dr. Myrna Germanos – Candidacy for National Representative of the Arab Federation of Clinical Biology (AFCB) to the IFCC**

On behalf of the **Lebanese Syndicate of Clinical Biologists (SDBL)**, it is with great enthusiasm and full confidence that we express our strong support for **Dr. Myrna Germanos** as a candidate for the position of National Representative of the Arab Federation of Clinical Biology (AFCB) to the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

Dr. Germanos is our **actual Syndicate's President** and she has consistently demonstrated exceptional dedication to the advancement of clinical biology both nationally and across the region. Her scientific expertise, leadership skills, and commitment to professional collaboration make her an ideal representative for our community on the international stage.

Through active participation in regional initiatives, contributions to scientific education, and advocacy for quality and innovation in laboratory medicine, Dr. Germanos has earned the respect of peers and institutions alike. We are confident that her representation within the IFCC would reflect the values and priorities of the Arab Federation and contribute positively to global dialogue and cooperation.

We are proud to endorse Dr. Myrna Germanos's nomination and firmly believe they will bring honor, insight, and active engagement to this important role.

Yours sincerely,

Dr Imad Itani
SDBL Secretary



Dr Christian Haddad

SDBL Past President. AFCB President

بنابة نقابة أطباء لبنان في بيروت – فرن الشباك – التحويطة- تلفون / فاكس: 01- 616661
Immeuble Ordre des Médecins – Furn el Chebbak – Tahwita – Beyrouth – Liban – Téléfax : 01-616661
Mobile: 71-992591
Email : info@sdblb.org – Website : www.sdblb.org



Rajiv ERASMUS

**SOUTH AFRICAN ASSOCIATION
FOR CLINICAL BIOCHEMISTRY AND
LABORATORY MEDICINE (SAACB)**



NOMINATION FORM for REGIONAL FEDERATION REPRESENTATIVE IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of SOUTH AFRICAN SOCIETY OF CLINICAL BIOCHEMISTRY (SAACB)
(insert name of National Society)

Name: PROF RIVAK PUNCHOO

Office held within the National Society: PRESIDENT
(This should normally be the nominated National Representative to the IFCC Council)

We nominate for the Office of AFCC Regional Federation Representative for the term 2027-2029

PROF RAJIV ERASMUS
(insert name of nominee)

Signature: 

Date: 23/06/2025

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, RAJIV ERASMUS
(insert name) accept nomination for election to the position of *Africa Federation of Clinical Chemistry* Regional Federation Representative.

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: Chemical Pathology, Stellenbosch University,
Phone: +27 83 601 5266

Fax: N/A

Email: rte@sun.ac.za

Signature: 

Date: 23/06/2025

3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues which you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

The International Federation of Clinical Chemistry (IFCC) is the biggest global organization of laboratory professionals. The immense value that laboratory professionals play in the diagnosis of disease etc has not been given its due importance. IFCC needs to create awareness both among health professionals and the lay public. We should therefore look for **opportunities to create programs that would highlight the important role** of laboratory professionals in the health arena. We should focus on **providing value** rather than just being a cost centre. We should also be **creating think tanks** that would **monitor emerging trends and use of novel technologies** in promoting earlier diagnosis of various diseases. This should then be shared with colleagues such that lab professionals will be in the forefront of evaluating their usefulness.

With the advent of **emerging technologies** IFCC should ensure, through the provision of training workshops, to educate lab professionals to harness these technologies and create value. Recent strategic meetings have proposed that with the introduction of **electronic medical records (EMR)** laboratory professionals should include recommendation for an **optimal tests battery** that could be used to help to rule in the most probable diagnosis, rule out the unlikely ones, and identify the **risks for life-threatening diseases**. We must educate **laboratory professionals in the use of AI and ML technology** such that they can be used not only in the test-selection phase but also to help interpret multidimensional test results, providing likelihood scores and probability scores for subclinical diseases. Laboratory professionals should be in the **forefront of big data analytics and artificial intelligence**. Greater emphasis by the IFCC should be placed on **personalized medicine and digitalisation**. In this regard IFCC needs to play a key role along with clinical colleagues in developing integrated diagnostics. **Integrated diagnostics** represents a cohesive approach to **disease-specific diagnostic pathways**, improving patient outcomes and operational efficiency. IFCC should continue to **promote green laboratory practices** by instituting incentives and a reward system in which laboratories are scored and recognised internationally for reducing environmental waste. On a global level **low cost diagnostics** has not been given adequate attention. As health care costs continue to escalate this is an opportunity for IFCC to engage with NGOs and corporates to develop low cost diagnostics

Finally I believe that more efforts must be made towards **overcoming language barriers**. As such IFCC webinars and conferences should also be given in Spanish, French and Chinese. Furthermore IFCC should also play a more targeted role in **education and training** particularly in the developing world where 80% of the world's population resides. In practical terms this means that there should be a concerted effort in increasing the **visibility of IFCC in its regional federations such as COLABICLI, AFCC, APFCB** and **more funding** should be made available for professional exchange programs and conference attendance from member societies from these respective regional federations. Quality training programs and **identifying challenges in developing** countries should be actively targeted. Finally we need to **encourage francophone countries** particularly from Africa to become members of IFCC

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as Regional Federation Representative. Font used should be Calibri; font size 11.

Throughout my career I have consistently been involved in professional activities at the local, national, regional and international levels. I have served on several IFCC Committees (see below) and been part of many IFCC supported publications. I have also organised several conferences and workshops

Positions

President of S African Association for Clinical Biochemistry (4 years)

President, Africa Federation of Clinical Chemistry (4 years)

Currently representing AFCC on IFCC EB and also the Liaison Officer between IFCC and TF-NBS

Conferences Organized

International: IFCC World Lab, Durban, S Africa – first ever IFCC conference to be held in Africa .

Africa Federation Regional Conference /Egylab– Cairo, Egypt.

Africa Regional Conference, Lusaka, Zambia

SAACB National Conferences X2

Regional: Point of Care Africa Conference (Kenya)

Regional: 4th Point of Care Africa International Colloquium (S Africa)

Federation of S African Societies of Pathology (FSASP) Conferences

Multiple Workshops in S Africa, Kenya, Ethiopia, Egypt

Committee Memberships (IFCC)

Point of Care

Reference Intervals and Decision Limits

Laboratory Management

Public Relations Committee (Chair)

Committee Memberships (AFCC)

Chair, AFCC Point of Care Committee (current)

Member, AFCC New Born Screening Committee (current)

I have played a key role in forming the Point of Care and Newborn screening committees within the Africa Federation of Clinical Chemistry (AFCC) and continue to assist the IFCC and AFCC to recruit new members from Africa. I have assisted all the African member societies in organising their academic programs whenever they have organised conferences. I have continued to support education and training activities in Africa for more than 15 years and have established along with young scientists, The African Young Scientist Forum. I have actively supported the award of multiple travel grants to young scientists from Africa. I co-organized the first IFCC WorldLab conference to be held in Africa in 2017

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

I have multiple interests that encompass many areas of laboratory medicine. These include the following:

Laboratory Management and Leadership: I established the first laboratory management course in South Africa in 2006. Since its establishment, it is now very much in demand and embraced by residents and other trainees who are specialising in laboratory medicine.. Laboratory professionals from Kenya, Ethiopia, Nigeria, Malawi, Zambia and Namibia have also participated . Linked to this is my interest in motivating young scientists to aspire to be leaders. In this regard I have been involved in organizing leadership and strategic planning workshops with the Task Force for Young Scientists (TF-YS)

Clinical Audits: To identify areas of improvement in the processing and delivery of laboratory results I established an audit group to identify areas that could be improved to improve laboratory efficiency and this resulted in several recommendations and publications. Many of these recommendations are relevant to African laboratories . Invitation to colleagues from African member societies was also sent.

Diabetes and Cardiovascular research: My interest in diabetes stretches as far back as the late 80s when I carried out the first survey of diabetes in rural Nigerians using fasting blood samples. Subsequently this was followed by surveys in Papua New Guinea and South Africa. In South Africa I established the Bellville South Study in 2007 (now known as Vascular and Metabolic Health Study) which investigated the presence of diabetes, cardiovascular risk factors, obesity, dyslipidaemia and metabolic syndrome in the mixed ancestry population of South Africa.

Reference Intervals Study in Kenya, Ghana and South Africa. I established the Reference Intervals Africa Study group and later joined the Global Reference Intervals Study initiated by Prof Kiyoshi Ichihara. This study established reference intervals in different African populations

Creating Awareness of Diagnostic Role of Laboratory Professionals : As chair of C-PR, I was involved in establishing the Global Medical Lab Week (Lab Saves Lives)which has now become one of the main focus areas of IFCC in the last 2 years

I believe that my rich and in-depth experience in various areas of laboratory medicine on the African continent as well as involvement in multiple IFCC activities will allow me to advance the mission of the IFCC particularly as it relates to advancing and improving the practice of laboratory medicine in improving patient care and outcomes, advancing scientific knowledge, facilitating collaboration with corporates and responding to global challenges in an effective manner

SAACB

Enquiries: saacb1@gmail.com Website: <http://www.saclinpath.co.za/>



The South African Association for Clinical Biochemistry

Postnet Suite #402
Private Bag X15
Menlo Park
0102

25 June 2025

Dear IFCC Executive Board
International Federation of Clinical Chemistry (IFCC)

Letter of Support for the Nomination of Prof. Rajiv Erasmus to Regional Federation Representative (AFCC) 2027–2029

Dear Members of the IFCC Executive Board,

On behalf of the South African Society of Clinical Biochemistry (SAACB), it is with great pleasure that I write this letter of support for the nomination of Professor Rajiv Erasmus for the position of Africa Federation of Clinical Chemistry (AFCC) Regional Federation Representative on the IFCC Executive Board for the term 2027–2029. Professor Erasmus is an eminent figure in laboratory medicine, with an exemplary career spanning leadership, academic excellence, and impactful service at national, regional, and international levels. He has served as President of both the SAACB and the AFCC, as well as a member of multiple IFCC committees, including Point of Care, Reference Intervals and Decision Limits, Laboratory Management, and the Public Relations Committee (where he served as Chair). His sustained commitment to the advancement of clinical chemistry in Africa is evidenced by his pivotal role in organizing milestone events such as the first-ever IFCC WorldLab Conference held in Africa (Durban, 2017), and numerous regional conferences and workshops across the continent.

Beyond his leadership credentials, Professor Erasmus has demonstrated an enduring commitment to capacity building and education. He has initiated pioneering programs in laboratory management and leadership training, facilitated the establishment of the African Young Scientist Forum, and provided mentorship that has nurtured the next generation of laboratory professionals across multiple African countries. His initiatives in point-of-care testing, newborn screening, diabetes and cardiovascular research, and reference interval studies have significantly advanced diagnostic capabilities and scientific understanding in resource-limited settings.

Professor Erasmus's vision aligns closely with IFCC's mission to advance excellence in laboratory medicine globally. His focus on integrated diagnostics, digitalisation, AI and machine learning applications in laboratory medicine, low-cost diagnostics, and green laboratory practices reflects a forward-looking approach that addresses both current and emerging global health challenges. Moreover, his advocacy for multilingual outreach and targeted educational support for developing countries underscores his commitment to inclusivity and equitable access to knowledge.

Enquiries: saacb1@gmail.com Website: <http://www.saclinpath.co.za/>
President: Prof R. Punchoo Secretary: Dr T. Satekge Treasurer: Prof T.S. Pillay

SAACB

Enquiries: saacb1@gmail.com Website: <http://www.saclinpath.co.za/>



Given his distinguished record of service, strategic vision, and unwavering dedication to the advancement of clinical chemistry in Africa and globally, I strongly endorse Professor Erasmus's candidacy for this vital role within the IFCC Executive Board. His appointment would not only strengthen Africa's representation but also contribute substantively to the global objectives of the IFCC.

Yours sincerely,



Prof Rivak Punchoo
President
South African Association of Clinical Biochemistry (SAACB)

Enquiries: saacb1@gmail.com Website: <http://www.saclinpath.co.za/>
President: Prof R. Punchoo Secretary: Dr T. Satekge Treasurer: Prof T.S. Pillay



Samuel VASIKARAN



AUSTRALASIAN ASSOCIATION FOR CLINICAL BIOCHEMISTRY AND LABORATORY MEDICINE (AACB) - AUSTRALIA



NOMINATION FORM for REGIONAL FEDERATION REPRESENTATIVE IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of ...Australasian Association for Clinical Biochemistry and Laboratory Medicine
(insert name of National Society)

Name: ...Greg Ward.....

Office held within the National Society: ...President.....
(This should normally be the nominated National Representative to the IFCC Council)

**We nominate for the Office of (APFCB)
Regional Federation Representative for the term 2027-2029**

.....Samuel Vasikaran.....
(insert name of nominee)

Signature:.....*Greg Ward*.....

Date: ...11 June 2025.....

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, Samuel Vasikaran

accept nomination for election to the position of (APFCB) Regional Federation Representative,
and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: PathWest-Fiona Stanley Hospital, Murdoch WA6150, Australia

Phone: +61 0415 444 742

Fax: +61 8 6152 8048

Email: samuel.vasikaran@health.wa.gov.au

Signature:.....*Samuel Vasikaran*..... Date: 10 June 2025



3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues which you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

As the APFCB regional representative on the IFCC EB, I would endeavour to support the IFCC EB in all its activities, while providing information and insights from the Asia-Pacific Region relevant to the functions of IFCC globally and particularly in the Asia-Pacific region. Providing support to both organisation by providing liaison between and support for coordination of the activities of APFCB with IFCC is the unique role of this office,

I see the role of IFCC globally as the peak body representing the healthcare laboratory science industry, which aims to improve healthcare systems worldwide and regionally. The Federation provides support to scientists, technicians, and pathologists in working towards these goals by supporting quality control and quality assurance activities as well as standardizing and harmonizing measurements and reporting. Improving laboratory management both in effectiveness in patient centered outcomes, and efficiency in both reducing costs as well as reducing waste and the healthcare carbon footprint are important aspects of laboratory management where IFCC has in the past, and should continue in the future, to provide leadership.

Education of laboratory professionals and especially young scientists through face to face as well as virtual meetings, workshops and other activities are critical to supporting the professional development of laboratory professionals and improving laboratory services.

Engaging with the corporate representatives and the industry to support them in their activities as well as providing education where required is critical to the partnership with the corporate sector.

The regional representative would focus on supporting the IFCC EB in playing an effective role in the AP region in all of the above areas, including through the coordination of activities with APFCB.

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as Regional Federation Representative. Font used should be Calibri; font size 11.

IFCC

Chair IFCC, Committee on Bone Metabolism 2025- current
Member, IFCC Committee on Bone Metabolism 2019 – 2024
Chair, IFCC Working Group on the Harmonisation of Interpretive Comments EQA 2015 – 2018
Member, IFCC Working Group on Standardisation of Bone Marker Assays 2012 – 2018
Chair, IFCC Working Group on Bone Marker Standards in Osteoporosis 2009 – 2011
Member, IFCC Committee on Clinical Laboratory Management 2008 – 2010

Asia Pacific Federation of Clinical Biochemistry (APFCB)

Vice President, January 2023 – current
Chair, APFCB Scientific Committee 2017 – 2022
Chair, APFCB Education Committee 2011 – 2013
Chair, APFCB Laboratory Management Committee 2008 – 2010
APFCB Travelling Lecturer 2009-2010

Australian Association of Clinical Biochemistry (AACB)

Geoffrey Kellerman award, 2020
Outstanding Service Medal, 2011
Nancy Dale Travelling Scholarship, 2003
Editor, The Clinical Biochemist Reviews, 2003-2011

As demonstrated above, I have functioned successfully in diverse capacities in scientific, educational and management roles both nationally and internationally within the national organisation as well as IFCC and APFCB. I am very familiar with the functioning of both IFCC and APFCB and hence able to successfully manage the APFCB regional representative role on the IFCC EB.

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

My scientific and clinical interests are in standardising or harmonizing bone related indices (PTH, BTM etc) and have provided leadership in this area nationally and in establishing a successful liaison with a clinical association (International Osteoporosis Foundation), with very productive outcomes in guideline and position statement publications and harmonizing methods for measurement.

Having established the EQA program for interpretative commenting in Clinical Chemistry within Australia and chaired the IFCC Working Group on the Harmonisation of Interpretive Comments with the publication of a major position paper, I have proven track record and a continuing interest in the improvement of the post-analytical phase.

I have participated successfully in many educational activities both through the APFCB travelling lectureship, as well as by speaking at many international conferences and through webinars and virtual meetings organised by IFCC, APFCB as well as AACB. I have a keen ongoing interest in Education and continuing professional development of Laboratory professionals.



**AUSTRALASIAN ASSOCIATION FOR CLINICAL
BIOCHEMISTRY AND LABORATORY MEDICINE**

OFFICE: 5/85 Bourke Rd, Alexandria NSW, 2015
PO Box 7336, Alexandria NSW, 2015
Telephone: +61 2 9669 6600 Email: office@aacb.asn.au

10 June 2025

IFCC Office
E: ifcc@ifcc.org

Letter of support for Dr Samuel Vasikaran, for nomination to the IFCC Executive Board, 2027-2029

Dear IFCC

The Australasian Association for Clinical Biochemistry and Laboratory Medicine (AACB) is pleased to nominate **Dr Samuel Vasikaran** for the position of **Regional Federation Representative (APFCB)** on the **IFCC Executive Board for the 2027–2029 term**.

Dr Vasikaran has shown an exceptional and sustained commitment to advancing clinical biochemistry and laboratory medicine through his leadership, scholarly contributions, and international collaboration.

Within the IFCC, he has held several significant roles, including Chair of the Committee on Bone Metabolism (2025–present), Member of the same committee (2019–2024), and Chair of the Working Group on Harmonisation of Interpretive Comments in EQA (2015–2018). He has also contributed extensively to initiatives focused on bone marker standardisation and laboratory management.

In the APFCB, Dr Vasikaran currently serves as Vice President (2023–present). Previously, he chaired the Scientific, Education, and Laboratory Management Committees (2008–2022) and was appointed Travelling Lecturer (2009–2010).

Nationally, his remarkable service to the AACB has been recognised with the Geoffrey Kellerman Award (2020) and the Outstanding Service Medal (2011).

Dr Vasikaran brings a wealth of experience and is exceptionally well-qualified to represent the region and contribute effectively at the executive level. AACB strongly endorses Dr Vasikaran.

Regards



Mr Greg Ward
President, AACB

Australasian Association for Clinical Biochemistry and Laboratory Medicine
P: (02) 9669 6600 | W: www.aacb.asn.au

Affiliated with the

*INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE
ASIA-PACIFIC FEDERATION FOR CLINICAL BIOCHEMISTRY AND LAB MEDICINE*



Eduardo Luis FREGGIARO

**CONFEDERACIÓN UNIFICADA DE
BIOQUÍMICA DE LA REPÚBLICA
ARGENTINA (CUBRA)**



NOMINATION FORM for REGIONAL FEDERATION REPRESENTATIVE IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of Confederación Unificada de Bioquímica de la República Argentina (CUBRA)

Name: Dr. Luis García

Office held within the National Society: President of CUBRA

**We nominate for the Office of COLABIOCLI
Regional Federation Representative for the term 2027-2029**

Eduardo Luis Freggiaro

Signature: Dr. Luis García (President of CUBRA)

Date: June 10th, 2025

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, Eduardo Luis Freggiaro

accept nomination for election to the position of COLABIOCLI Regional Federation Representative.

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address: Juan Carlos Cruz 1643
Ap. 301
ZIP 1643
Vicente López, Buenos Aires (Argentina)

Phone: +54 11 3110-8776

Fax: NA

Email: freggiaro@gmail.com

Signature:

Date: June 10th, 2025

3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statement should outline issues which you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

For nearly the past two years, I have served as the COLABIOCLI representative on the Executive Board (EB) of the IFCC. This position has allowed me to engage more directly with national representatives and presidents across the region, giving me first-hand insight into the realities, strengths, and challenges faced by clinical laboratories and professionals in our Latin American countries.

In the global context, our region is gaining increasing prominence. We are known for being resilient, creative, and committed to continuous improvement, even in complex environments. We should not hesitate to propose our working models—many of which have proven effective in our countries—so that they may be considered by other IFCC members facing similar challenges. I firmly believe we can and must be key players in shaping the federation's global strategies.

Being part of the EB has given me a deeper understanding of the major issues shaping the future of laboratory medicine: the shift toward value-based healthcare models, the ethical and effective implementation of artificial intelligence, the need to strengthen lifelong professional education, and the importance of ensuring quality, equity, and sustainability in laboratory services. Our region must actively prepare to face these challenges by adapting international frameworks to local realities, while upholding global standards.

My personal commitment is to continue working with responsibility, an integrative vision, and the same enthusiasm with which I began this role. I believe Latin American representation must be active, proactive, and strategic. I am convinced that collective knowledge, international cooperation, and respect for diversity are key to advancing toward a more efficient, innovative, and patient-centered laboratory medicine.

As regional representative, my priority will be to maintain open and horizontal communication with the member countries of COLABIOCLI, to promote the participation of young professionals, to support initiatives that strengthen our scientific societies, and to serve as an effective bridge between IFCC and our region. I will continue to dedicate my work ethic, openness to change, and strong commitment to laboratory medicine in the service of better health for all.

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as Regional Federation Representative. Font used should be Calibri; font size 11.

My involvement with IFCC began in 2010 as a member of the former Committee on Internet and e-Learning (C-leL), where I served as Social Media Coordinator. During this time, I also contributed to the development of the IFCC eAcademy, an innovative project that expanded the Federation's global educational reach. After six years of active participation, I was appointed Chair of the same committee and simultaneously served as Secretary of Publications and Communications within the Communications and Publications Division (CPD).

During my CPD years, I was part of the Working Group on Global Lab Week (WG-GLW), where I collaborated in the promotion of laboratory medicine worldwide. Since joining the CPD, I have also acted as the liaison between the Working Group on the International Network of Clinical Laboratory Professionals and Technicians (WG-IANT) and the CPD, supporting communication efforts particularly with Spanish-speaking members and societies.

In 2022, I was elected as Regional Representative of COLABIOCLI at the EB of IFCC. This is the position that I would like to continue for a second term of service.

Having served in various functional units over the past 15 years, I have developed a deep understanding of the structure, mission, and operational dynamics of IFCC. This experience has given me the tools to effectively connect with national societies and communicate the Federation's vision throughout Latin America. I am strongly committed to strengthening these ties, ensuring that IFCC's initiatives are both visible and meaningful at the regional level.

In parallel with my service to IFCC, I have been actively involved in COLABIOCLI's educational and scientific initiatives. I was a member of the Scientific Committee of the most recent COLABIOCLI Congress, held in Cartagena, Colombia, and contributed to the development of online courses on Laboratory Quality Management.

Currently, I serve as President of the Fundación Bioquímica Argentina (FBA), which became an IFCC Affiliate Member in 2024. In Argentina, I am also collaborating in the organization of the upcoming National Congress of CUBRA, a key event for the professional community in our country.

My previous service within IFCC, COLABIOCLI, and FBA has equipped me with the experience, insight, and dedication required to serve effectively as Regional Federation Representative. I remain committed to fostering meaningful connections between IFCC and the Latin American clinical laboratory community.

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

Throughout my professional career, I have cultivated a deep interest in clinical biochemistry, continuing education, digital innovation, and the use of emerging technologies to improve laboratory medicine. My formal education includes a degree in Biochemistry from the University of Buenos Aires and a postgraduate diploma in Education and New Technologies from FLACSO–UNESCO, which laid the foundation for my dedication to combining science, communication, and education.

My major professional and scientific interests have long focused on digital transformation and innovation in education. Since 2004, I have led the eLearning program of the Fundación Bioquímica Argentina (FBA), offering postgraduate training in clinical biochemistry to professionals across Argentina and Latin America. This initiative was one of the first of its kind in the region and has contributed significantly to the continuing professional development of laboratory specialists.

In 2015, I founded and have since co-directed Virtualab, the first fully virtual congress on clinical biochemistry. Recognized by IFCC and AACC as a pioneering event, Virtualab gathers more than 1,500 participants from across the region every two years. These experiences reflect my ongoing commitment to building inclusive, accessible scientific platforms that align with IFCC's mission to promote international education and knowledge sharing.

My academic background also includes over two decades of university teaching in physics and scientific communication, and my work in the IFCC has allowed me to extend these interests globally. I contributed to the launch of the IFCC eAcademy and served as Chair of the Committee on Internet and Digital Communications (C-IDC) and Secretary of Publications and Communications in the CPD. I have also given presentations at various national and international congresses and events, including symposia and round tables, and had the honor of delivering several plenary lectures at regional conferences.

In recent years, I have expanded my interests toward data science, big data analytics, and artificial intelligence as applied to laboratory medicine—areas that are increasingly critical for the future of our profession and closely aligned with IFCC's strategic objectives.

Today, as President of the Fundación Bioquímica Argentina (an IFCC Affiliate Member since 2024), I continue to promote innovation, education, and regional collaboration. I am also involved in organizing national and regional scientific events, including the upcoming CUBRA Congress and the most recent COLABIOCLI Congress in Cartagena.

These combined interests and experiences will allow me to actively contribute to the mission of IFCC, strengthening its presence and impact across Latin America.



Confederación Unificada Bioquímica de la República Argentina

PERSONERÍA JURÍDICA RESOLUCIÓN I.G.J. 358467 | Representaciones Nacionales:

IFCC

International Federation of Clinical
Chemistry and Laboratory Medicine

COLABIOCLI

Confederación Latinoamericana
de Bioquímica Clínica

Buenos Aires, 10th June 2025

Dear Leslie Lai
Chair Nominations Committee (EB-NC)

On behalf of CUBRA, the National Society full member of IFCC, we support the nomination of Dr. Eduardo Freggiaro as a candidate to continue in the position of regional representative of COLABIOCLI on the IFCC Executive Board.

I base my request on his curriculum as well as her ability, willingness to work, responsibility, honesty and professionalism, I am confident that he will continue to providing an excellent support and contributing to the IFCC's projects.

In case of anything else, do not hesitate to contact us.

Best regards,



Dr. Luis A. García
Presidente CUBRA

Av. Rivadavia 2319 11° P - "A" - (1034) - CABA | Tel. +54 11 4951 9907 / +54 11 4952 7599 | cubra@cubra.info | www.cubra.info



COLABIOCLI
Confederación Latinoamericana
de Bioquímica Clínica

**COMITÉ EJECUTIVO
2024 – 2026**

Presidente
Dr. Julio Nieto Ramos
Panamá

Vicepresidente
Dra. Marlene Vélez
Colombia

Secretario General
Mgter. John Jairo Córdoba
Panamá

Tesorera:
Mgter. Gloria Y. Saucedo B.
Panamá

Vocal 1ro.:
BQ Carmen E. Troche Paraguay

Vocal 2do.:
QFB. María Elena George R.
México

Vocal 3ro.:
Dra. Patricia Erazo Mayorga
Ecuador

**Comisión Revisora
de Cuentas**

Dra. María E. Santos Mojica
República Dominicana

Dra. Vivian L. Matta
Guatemala

Dr. Álvaro Justiniano Grosz
Bolivia

PAISES INTEGRANTES:

Argentina – Bolivia – Brasil – Colombia – Costa Rica – Chile – Ecuador – El Salvador - España -
Guatemala – Honduras – México – Nicaragua – Panamá - Paraguay – República Dominicana –
Uruguay

Nota 044/2025

Panamá, 10 de junio de 2025

A quien corresponda,

Por medio de la presente, el Comité Ejecutivo de COLABIOCLI expresa su total respaldo a la postulación del Dr. **Eduardo Freggiaro** para la renovación de su cargo como **miembro del Executive Board de la IFCC**, en representación de nuestra región.

El Dr. Freggiaro ha demostrado un compromiso sólido y una destacada labor en la promoción de los intereses y el desarrollo científico de los países latinoamericanos dentro de la IFCC. Su liderazgo, experiencia y activa participación han sido claves para fortalecer la presencia regional y generar valiosas oportunidades de colaboración internacional.

Estamos convencidos de que su continuidad en el cargo será de gran beneficio para COLABIOCLI y para la comunidad global de la química clínica.

Sin otro particular, reiteramos nuestro apoyo y quedamos a disposición para cualquier información adicional.

Atentamente,



Dr. Julio Nieto R.
Presidente COLABIOCLI



Mgter. John Jairo Córdoba
Vicepresidente COLABIOCLI



Carmen E. Troche CABALLERO



**ASOCIACIÓN DE BIOQUÍMICOS
DEL PARAGUAY (ABP)**



NOMINATION FORM for REGIONAL FEDERATION REPRESENTATIVE IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of Association of Biochemists of Paraguay (ABP)
(insert name of National Society)

Name: Dr. José Pereira Brunelli

Office held within the National Society: ABP President and National Representative to the IFCC,
Paraguay
(This should normally be the nominated National Representative to the IFCC Council)

**We nominate for the Office of (COLABIOCLI)
Regional Federation Representative for the term 2027-2029**

Dr. Carmen Elizabet Troche Caballero
(insert name of nominee)

Signature: Dr. José Pereira Brunelli.

Date: June 27, 2025

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, Carmen Elizabet Troche Caballero
(insert name)

accept nomination for election to the position of (COLABIOCLI) Regional Federation Representative.

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

Address:
San Cosme, B° Jara , Asuncion , Paraguay

Phone: +595981230107

Fax:

Email: carmentrocheder 2016@gmail.com

Signature: Date: June, 27, 2025

3. Statement of Intent

I, Dr. Carmen Elizabet Troche, respectfully submit my declaration of intention to serve as Regional Federation Representative of COLABIOCLI to the IFCC Executive Board for the 2027–2029 term.

My vision is grounded in personalizing, country-by-country engagement. Over the last decade I have cultivated close working relationships with the National Societies of Latin America and the Iberian Peninsula. As First Vocal of COLABIOCLI and former Vice-President of the Association of Biochemists of Paraguay (ABP), I have witnessed first-hand the diverse realities that shape laboratory medicine in our region. If elected, I will visit—or meet virtually with—each Society during the first year of the mandate to agree on tailored action plans that align local priorities with IFCC goals.

Those IFCC goals—advancing excellence in laboratory medicine, fostering education, harmonizing quality standards, and improving global health—form the backbone of my program:

- **Education & Knowledge Transfer** – Coordinate regional webinars and bilingual workshops that leverage IFCC Academy content, ensuring access for young scientists and resource-limited institutions.*
- **Quality & Standardization** – Promote adoption of ISO 15189 and external quality assessment by partnering with IFCC Scientific Divisions to provide bespoke mentoring and share reference materials.*
- **Innovation & Digital Transformation** – Encourage integration of digital health, artificial intelligence and data connectivity projects showcased by IFCC Task Forces, accelerating their translation into daily practice.*
- **Sustainability & Outreach** – Support environmentally responsible laboratory practices and expand collaborative outreach programo to undeserved communities, aligning with IFCC's commitment to better health worldwide.*

During the 2026 transition year I will work closely with the current Regional Representative, the COLABIOCLI Executive Board and IFCC Office to guarantee continuity. Regular progress reports will be shared with both organizations, reinforcing transparency and accountability.

4. Statement of Service

I have dedicated my professional career to ensuring that the scientific advances and educational resources generated by IFCC reach every corner of Latin America. During my tenure as President of the Association of Biochemists of Paraguay (ABP) I acted as Paraguay's National Representative to IFCC, serving as an effective conduit between the Federation and our local community. I translated policy updates, organized webinars, and developed a monthly IFCC news bulletin that reached more than 1 200 professionals nationwide. Under my leadership the number of Paraguayan abstracts accepted at IFCC-endorsed congresses doubled.

I also spearheaded ABP's participation in Global Med Lab Week from its first edition, coordinating public outreach events and achieving record social-media engagement for our federation. Recognizing the value of international exposure, I mentored young scientists, secured travel bursaries, and accompanied the first Paraguayan delegation to EuroMedLab. Four awardees later assumed leadership roles in their hospital laboratories, tangible proof of the multiplier effect that strategic support can create.

Within COLABIOCLI I have continued to amplify IFCC programs. As First Vocal on the Executive Board I manage regional communication channels, ensuring timely translation and dissemination of IFCC Academy courses, task-force surveys, and calls for collaboration. Registration from our member countries in IFCC webinars grew by 63% in the last two years, a reflection of our coordinated outreach.

This record of service underlines three core competencies that I will bring to the position of Regional Federation Representative: (1) Proven ability to build bridges and communicate across cultures; (2) Hands-on experience mobilizing resources for education and quality improvement; and (3) Commitment to transparency and timely reporting. If elected I will expand personalized mentoring, reinforce regional participation in IFCC scientific divisions, and implement an annual dashboard to track progress against Federation goals. Guided by IFCC's mission of advancing laboratory medicine for better patient care, I am ready to serve with renewed energy and broader reach.

5. Statement of Interests

Throughout my career I have been driven by a commitment to elevate the standards, visibility and impact of clinical laboratory medicine across Latin America. My professional interests converge in three interconnected domains—continuous education, quality improvement, and scientific collaboration—all of which align directly with the IFCC mission of advancing excellence in laboratory medicine for better healthcare worldwide.

1. ****Continuous Education & Capacity Building**** – As Vice President (and former President) of the Paraguayan Association of Clinical Biochemistry (ABP), I established a year-round program of hybrid scientific meetings and journals clubs that now reach professionals in every region of Paraguay. I champion scholarships for young scientists to attend IFCC-endorsed congresses and training courses; six awardees have since published in peer-reviewed journals and assumed leadership roles in their institutions. My goal is to expand this mentorship model region-wide through COLABIOCLI, leveraging IFCC Academy resources and Task Force expertise.

2. ****Quality Improvement & Standardization**** – I am passionate about implementing ISO 15189 and external quality assessment schemes. Within ABP I led workshops that helped three national laboratories initiate accreditation roadmaps. As First Vocal on the COLABIOCLI Executive Board I coordinate dissemination of IFCC guidelines and promote participation in global standardization initiatives, thereby reducing analytical variability and improving patient outcomes.

3. ****Scientific Collaboration & Innovation**** – My clinical research interests include biomarkers for metabolic syndrome and the application of digital health tools in low-resource settings. By encouraging multicenter collaboration and embracing technologies such as remote learning and data connectivity, I seek to close knowledge gaps that once seemed insurmountable. With proven leadership at both national and regional levels, and full availability for virtual and face-to-face meetings, I am prepared to dedicate the next three years to serving as a strong, responsive link between IFCC and the 14 National Societies of COLABIOCLI. If elected Regional Federation Representative I will harness these interests to strengthen the bridge between IFCC and COLABIOCLI: facilitating knowledge exchange, accelerating quality initiatives, and nurturing young talent. Together we can ensure that every laboratory professional in our region has the opportunity to contribute to—and benefit from—the global community of excellence fostered by IFCC.

LETTER OF SUPPORT

Asunción, 27 of June, 2025

Subject: Letter of institutional support for the candidacy of Dr. Carmen Elizabet Troche

Professor Leslie Lai
Chair, IFCC Nominations Committee
Federation of Clinical Chemistry and Laboratory Medicine (IFCC)

Dear Professor Lai,

On behalf of the Association of Biochemists of Paraguay (ABP), it is an honor to express our full and enthusiastic support for the candidacy of Dr. Carmen Elizabet Troche Caballero for the position of COLABIOCLI Regional Representative to the IFCC.

Dr. Troche is a highly distinguished professional and a woman of great integrity, who has dedicated many years of committed service to the APB. She currently serves as our Vice President and previously held the position of President, during which she significantly contributed to the national and international development of our Association.

Her exceptional leadership and dedication to the professional advancement of her colleagues in Paraguay have been evident in every role she has undertaken. Furthermore, her efforts and active engagement have extended beyond our borders, as she now also serves as a member of the Executive Committee of COLABIOCLI, working tirelessly for the benefit of clinical biochemistry professionals across Latin America.

We are confident that Dr. Troche will represent COLABIOCLI with the highest level of commitment, professionalism, and distinction at the IFCC. Her vision, experience, and spirit of collaboration make her an ideal candidate to contribute meaningfully to the global advancement of clinical laboratory sciences.

We wholeheartedly endorse Dr. Troche's candidacy and appreciate your consideration of her nomination.

Sincerely,



Dr. José Pereira Brunelli
President
Association of Biochemists of Paraguay (ABP)



COLABIOCLI
Confederación Latinoamericana
de Bioquímica Clínica

**COMITÉ EJECUTIVO
2024 – 2026**

Presidente
Dr. Julio Nieto Ramos
Panamá

Vicepresidente
Dra. Marlene Vélez
Colombia

Secretario General
Mgter. John Jairo Córdoba
Panamá

Tesorera:
Mgter. Gloria Y. Saucedo B.
Panamá

Vocal 1ro.:
BQ Carmen E. Troche Paraguay

Vocal 2do.:
QFB. María Elena George R.
México

Vocal 3ro.:
Dra. Patricia Erazo Mayorga
Ecuador

**Comisión Revisora
de Cuentas**

Dra. María E. Santos Mojica
República Dominicana

Dra. Vivian L. Matta
Guatemala

Dr. Álvaro Justiniano Grosz
Bolivia

PAISES INTEGRANTES:

Dra. Carmen Elizabet Troche
Primera Vocal – COLABIOCLI
Vicepresidente – Asociación de Bioquímicos del Paraguay (ABP)
Presente.-

**Asunto: Respaldo institucional a candidatura como Representante Regional de
COLABIOCLI ante IFCC (2027–2029)**

Estimada Dra. Troche:

Reciba un cordial saludo en nombre del Comité Ejecutivo de COLABIOCLI y en el mío propio.

Hemos recibido con agrado su comunicación, mediante la cual expresa su intención de postularse como candidata al cargo de Representante Regional de COLABIOCLI ante la IFCC para el período 2027–2029. Nos complace confirmar el respaldo institucional a su candidatura, en reconocimiento a su compromiso sostenido con la región, su activa participación en nuestra Confederación y su destacada trayectoria gremial y científica.

Desde su posición como Primera Vocal de COLABIOCLI y como Vicepresidenta de la Asociación de Bioquímicos del Paraguay, ha demostrado una valiosa capacidad de liderazgo, promoviendo iniciativas que fortalecen la integración regional y el desarrollo de nuestra profesión. Estamos convencidos de que su postulación representa una excelente oportunidad para consolidar la presencia latinoamericana en los espacios internacionales de toma de decisiones.

En tal sentido, le haremos llegar la carta oficial de apoyo institucional que usted ha solicitado, conforme a los lineamientos establecidos por la IFCC.

Le reiteramos nuestros mejores deseos de éxito en este nuevo desafío, y cuenta con el respaldo pleno de COLABIOCLI para continuar proyectando el prestigio y el talento de nuestra región.

Con sentimientos de aprecio y consideración,



Dr. Julio Nieto R.
Presidente COLABIOCLI



Mgter. John Jairo Córdoba
Secretario COLABIOCLI

Argentina – Bolivia – Brasil – Colombia – Costa Rica – Chile – Ecuador – El Salvador - España -
Guatemala – Honduras – México – Nicaragua – Panamá - Paraguay – República Dominicana -
Uruguay

Nota 052/2025

Panamá 27 de Junio de 2025



Thomas ZIMA

**CZECH SOCIETY
OF CLINICAL BIOCHEMISTRY
(CSKB) - CZECH REPUBLIC**



NOMINATION FORM for REGIONAL FEDERATION REPRESENTATIVE IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination by National Society

On behalf of The Czech Society of Clinical Biochemistry
(insert name of National Society)


Name: Richard Pikner, MD, PhD

Office held within the National Society: National Representative of IFCC
This should normally be the nominated National Representative to the IFCC Council

**We nominate for the Office - The European Federation of Clinical Chemistry and Laboratory
Medicine Regional Federation Representative for the term 2027-2029**

Prof. Tomáš Zima, MD, DSc

(insert name of nominee)

Signature: 

Date: 10 JUNE 2025

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, Tomáš Zima
(insert name)

accept nomination for election to the position of **The European Federation of Clinical Chemistry
and Laboratory Medicine** Regional Federation Representative.

and accept the obligations and time commitment required for this position, if elected.

My contact details are:

prof. Tomas Zima, MD, DSc.

Institute of Medical Biochemistry and Laboratory Medicine of the First Faculty of Medicine,

Charles University and General University Hospital, Prague

U Nemocnice 2

CZ-121 08 Prague 2

Czech Republic

Phone: +420-603 720 759

E-mail: zimatom@cesnet.cz

Signature:  Date: 10-06-2025

3. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the National Societies. The statements should outline issues which you see as important for the IFCC and how you might address them. Font use should be Calibri; font size 11.

The times ahead of lab medicine are very exciting and challenging. My priority for Federations will be – **naturally with your help** – to promote added value of laboratory medicine – value for clinical decision and also for cooperation with other medical disciplines. We should align with the “choose wisely” campaign to be able to use the laboratory resources in a best possible way. We take into account that laboratory medicine can improve **the delivery of quality of care** and benefits for the wellbeing and, of course, for patients and our staff safety.

Science in laboratory medicine will be focused on predictive, preventive and personalized medicine together with other scientific societies, research universities and alliances. IFCC, together with regional federations, should be the leading force in **research in laboratory medicine** - value based, health centred, science led, big data with application to daily health care practice.

New **emerging technologies** including – MS, biochips, nanotechnology, digital pathology, and new trends in molecular biology will be more implemented in daily laboratory practice and to establish or boost links and cooperation with the clinical associations, international institutions, industry (pharma, biomedical devices, information system, AI, etc.); the main aim of all of us is to focus on patients centered medicine worldwide and better appreciation and **importance of laboratory medicine in the society and the world as well.**

The key role of IFCC is **education and training** of our professionals, other health care professionals and patients. We should put together our forces in all continents with exchange and developing new educational sources using modern platforms and sharing the best practice between the whole world.

We should be more focused on and supportive for our future development - **the young scientists** and more involved them to our activities.

In the very complex world of healthcare, AI tools can support lab professionals to provide faster service, diagnose issues and analyze data to identify trends or genetic information that would predispose someone to a disease. AI and machine learning can be transformative not only for healthcare but for every single patient. We live in a **digital world**, which will have more and more influence on our daily laboratory life, which include - new type of communication between us but mainly with our patients - mobile health. Integration care and medical data “big data” is a great challenge and an opportunity, as well as ethical aspects and data security and protection.

Strengthening cooperation both inside (national societies and regional federations) and outside with other international societies, patient organizations, corporates, and other stakeholders; **building links, better communication and sharing the best practices and innovation in health between the Federations.**

Now I would be happy if you give me the opportunity to use my management, laboratory, clinical, scientific, teaching and communication skills for IFCC as regional representative of European Federation of Clinical Chemistry and Laboratory Medicine, as future President EFLM.

4. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the National Societies. The statement should describe how your previous service will contribute to your success as Regional Federation Representative. Font used should be Calibri; font size 11.

Professor Zima has been intensively serving in field of **clinical chemistry and laboratory medicine** on national and international level for more than 25 years in many positions, e.g.:

IFCC – International Federation of Clinical Chemistry and Laboratory Medicine

Committee on Conferences and Congresses IFCC - corresponding member 2009-2013,
full member 2014-2019

Education and Management Committee - Executive Committee member, secretary 2021-2026

Awards Committee (EB-AC 2018-23)

Member of Speakers Bureau

EFLM– European Federation of Clinical Chemistry and Laboratory Medicine

Member of Executive Board 2011-2019,

President Elect 2024-2025,

President of EFLM 2026-2027,

Member TFG-CKD Laboratory Diagnostics of Chronic Kidney Diseases from 2019

Member Congresses and Postgraduate Education Working Group (WG-CPE) 2010-2012

Member EFLM Speakers bureau

Member TFG-CKD Laboratory Diagnostics of Chronic Kidney Diseases from 2019

Czech Society of Clinical Biochemistry

President 2006 – 2014,

Member of Board from 2014

Professor Zima participated in organization of congresses as a member of Congress Organizing Committee (Worldlab Istanbul 2014, Euromedlab Athens 2017, Munich 2021, Rome 2023, London 2027) and as a member of International Scientific Advisory Board of many scientific congresses and co-founder and organizer of CELME 2015, 2017, 2019, 2021, 2023.

5. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the National Societies. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

Professor Tomas Zima, MD, DSc. Dr.h.c. (b. 1966) has been graduated at the First Faculty of Medicine, Charles University, Prague in 1990; he was appointed as **Professor of Medical Chemistry and Biochemistry in 2001**. He is the Head of Institute of Medical Biochemistry and Laboratory Medicine of the First Faculty of Medicine, Charles University and General University Hospital, Prague. Professor Zima has long term **teaching experience** in field of biochemistry, medical chemistry, pathobiochemistry, clinical chemistry and laboratory medicine. He is a specialist in clinical chemistry, internal medicine and nephrology and registered as European Specialist in Laboratory Medicine (EuSpLM). He is also Master of Business Administration - Prague International Business School (2003). He acted as Dean of the First Faculty of Medicine, Charles University in the years 2005-2012 and Rector of Charles University, Prague in the years 2014-2022. He was visiting professor Universita degli Studi di Milano in 2024.

His main research interests include oxidative stress, AGE's, experimental nephrology, tumor markers, prenatal screening, laboratory management and accreditation. He authored/co-authored more than 550 scientific articles (which are quoted more than 4900 times according to SCI, H-index is 39), 10 books (e.g. e.g. Zima, T., Weisstub, D. N., (Eds). Medical Research Ethics: Challenges in the 21st Century. Springer, 2023,) and 83 chapters in books. He delivered more than 200 lectures abroad.

He gained numerous awards in the Czech Republic (prizes of Czech Society of Clinical Chemistry, the prize of Praesidium of Czech Medical Association for monography Laboratory diagnostics) and also abroad among which, Professor Honoris Causa, State Medical University JY. Horbachevski in Ternopol (Ukraine), ESBRA Peter Berner Award (2011), doctor honoris causa - Uzhorod National University - Ukraine (2016), and Prešov University - Slovakia (2016).

Professor Zima is a member of many **learned, universities and scientific societies** (Academia Europea, Federation of European Biochemical Societies, Czech Medical Academy, The Learned Society of the Czech Republic) and serves in their boards. He worked in Alliance for Biomedical Research in Europe - European Council for Health Research - a member Core Working Group (2011-2012) and he has been a member of the European Commission's Scientific Panel for Health (SPH) since 2014- 2020 and **member Health Research Committee Biomed Alliance from 2023**. He was EUROPEUM member of Board of Trustees, member of Academic Council 2016 - 2022, president of 4EU+ University Alliance 2020-2021, and Board member of UNICA and Coimbra Group.

www.cskb.cz
sekretariat@cskb.cz



CZECH MEDICAL ASSOCIATION J. E. PURKYNE

CZECH SOCIETY OF CLINICAL BIOCHEMISTRY

President:

Assoc. Prof. Drahomira Springer, PhD
Inst. of Medical Biochemistry & Lab. Med.
First Faculty of Medicine Charles University
and General University Hospital
U Nemocnice 2
CZ-128 08 Prague 2
Phone: +420 224 962 883
Fax: +420 224 962 848
E-mail: springer@vfn.cz

Vice-President:

Prof. Jaroslav Racek, MD, DSc.
Inst. Clin. Biochem. & Hematol.
Charles University Hospital
Alej Svobody 80
CZ-304 60 Pízeň
Phone: +420 377 104 233
Fax: +420 377 104 234
E-mail: racek@fnplzen.cz

Vice-President, IFCC, EFLM representative:

Richard Pikner, MD, PhD
Department of Clinical Laboratories and Bone
Metabolism
Klatov Hospital
Pízeňská 929
CZ-339 01 Klatovy
Phone: +420 376 335 875
E-mail: pikner@nmkt.cz

Secretary:

Pavel Malina, MD PhD.
Department of Clinical Biochemistry
Pisek Hospital
Karla Capka 589
CZ-397 01 Pisek
Phone: +420 382 772 120
E-mail: malina@nemopisek.cz

Treasurer:

Daniel Rajdl, MD Ph.D.
Inst. Clin. Biochem. & Hematol.
Charles University Hospital
Alej Svobody 80
CZ-304 60 Pízeň
Phone: +420 377 104 285
Fax: +420 377 104 234
E-mail: rajdl@fnplzen.cz

Member-at-Large:

Prof. David Friedecký, PhD
Laboratory of Inherited Metabolic Disorders
Olomouc University Hospital
I.P. Pavlova 6
CZ-775 20 Olomouc
phone 588442619
E-mail: david.friedecky@fnol.cz

Member-at-Large:

Prof. Tomáš Zima, MD, DSc.
Inst. of Medical Biochemistry & Lab. Med.
First Faculty of Medicine Charles University
and General University Hospital
U Nemocnice 2
CZ-128 08 Prague 2
Phone: +420 224 962 842
Fax: +420 224 962 848
E-mail: zimatom@cesnet.cz

Section of Laboratory Technicians-charmain:

Mgr. Martina Bunešová
Dept. of Med. Chem & Clin. Biochem.
University Hospital Motol
V Úvalu 84
CZ-150 06 Praha 5
Phone: +420 224 435 318
Fax: +420 224 435 320
E-mail: martina.bunesova@fnmotol.cz

Technical Secretariat:

Miroslava Beranová
Inst. of Medical Biochemistry & Lab. Med.
First Faculty of Medicine Charles University
and General University Hospital
U Nemocnice 2
CZ-128 08 Prague 2
Phone: +420 224 962 841
Fax: +420 224 962 848
E-mail: sekretariat@cskb.cz

To whom it may concern

Letter of support from the National Society

10th June 2025

Dear colleagues,

On behalf of the Czech Society of Clinical Biochemistry let me nominate and highly recommend professor Tomáš Zima for the position of EFLM representative in the IFCC Executive Board.

Professor Zima has intensively served in field of clinical chemistry and laboratory medicine on national and international level for more than 20 years. He is the leading person in clinical biochemistry in the Czech Republic. He has published as main author 10 books and as co-author of 81 chapters in books, 331 original articles, 161 review articles, and his H-index is 38. Addition to that he is a hardworking person and excellent, communicative and listening manager.

He has demonstrated his management and communication skills in different positions as:

- EFLM President Elect 2024 -2025
- Member of EFLM Executive Board (2011-2019), IFCC-Congress and Conferences Committee (2014-2019) Education and Management Division (2021-2023)
- Member of Scientific Panel for Health EU 2014-2020
- Past president of the Czech Society of Clinical Biochemistry, board member since 1997
- President of 4EU+ University Alliance 2020-2021
- Rector of the Charles University Prague 2014-2020, Dean of the First Faculty of Medicine, Charles University Prague 2005-2012
- Since 1991 Head of the Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty, Charles University and General University Hospital Prague.
- President of national and international conferences (CELME, FEBS etc.)

Tomas Zima's main success is in building links among physicians, scientists and technicians, both in practical and theoretical laboratory settings.

He has been engaging bilaterally with healthcare stakeholders for many years to strengthen our profession and its role in healthcare.

The Czech Society of Clinical Biochemistry is proud to nominate Tomáš Zima as a candidate for the position of EFLM representative in the IFCC Executive Board.

Best regards



Richard Pikner, M.D., Ph.D.

Vice-president and EFLM, IFCC representative



IFCC

*International Federation
of Clinical Chemistry
and Laboratory Medicine*

**CORPORATE
MEMBERS
Representative
Nominations
2027 - 2029**

CANDIDATES

Nominees

Company

Tiffany JIANG

| Beijing Wantai Biological
Pharmacy Enterprise Co.Ltd.

Lucy LIU

| SNIBE - Shenzhen New Industries
Biomedical Engineering Co., Ltd.

Tricia RAVALICO

| Abbott Diagnostics



Tiffany JIANG

BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.



NOMINATION FORM for CORPORATE REPRESENTATIVE IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination

On behalf of : ...Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd...
(Please insert name of your company)
a Corporate Member of the International Federation of Clinical Chemistry and Laboratory Medicine,

I nominate: ...Tiffany Jiang...
...the General Manager of Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd...
...No.31 Kexueyuan Road, Changping District, Beijing 102206, China...

(Please insert title, name, company affiliation and address of nominee)

to the position of Corporate Representative on IFCC Executive Board for the term 2027-2029.

...Mr. Zixin Qiu...
...Chairman of the Board...
...Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.....

(Please insert your own name and position within the company)

Signature:

Date: 27.06.2025

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, ...Tiffany Jiang...
(insert name)

accept the above nomination. I declare that I am an employee of a Corporate Member of IFCC.

Signature Date 27.06.2025

3. Consent by Nominee's Employer

On behalf of: ...Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd...
(Please insert name of company)

I confirm that we consent to the above nomination to the position of Corporate Representative on IFCC Executive Board for the term 2027-2029.

Name: ... Zixin Qiu ...

Position in Company: ...Chairman of the Board...

Signature Date 27.06.2025





NOMINATION FORM for CORPORATE REPRESENTATIVE IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination

On behalf of : ...Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd...
(Please insert name of your company)
a Corporate Member of the International Federation of Clinical Chemistry and Laboratory Medicine,

I nominate: ...Tiffany Jiang...

...the General Manager of Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd...

...No.31 Kexueyuan Road, Changping District, Beijing 102206, China...

(Please insert title, name, company affiliation and address of nominee)

to the position of **Corporate Representative on IFCC Executive Board for the term 2027-2029.**

...Mr. Zixin Qiu...

...Chairman of the Board...

...Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd.....

(Please insert your own name and position within the company)

Signature:.....

Date:

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, ...Tiffany Jiang...
(insert name)

accept the above nomination. I declare that I am an employee of a Corporate Member of IFCC.

.....
Signature

.....
Date

3. Consent by Nominee's Employer

On behalf of: ...Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd...
(Please insert name of company)

I confirm that we consent to the above nomination to the position of **Corporate Representative on IFCC Executive Board for the term 2027-2029.**

Name:... Zixin Qiu...

Position in Company: ...Chairman of the Board...

Signature

Date

4. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the Corporate Members. The statement should outline issues which you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

First of all, please allow me to introduce my working and educational experiences.

WORKING EXPERIENCES

2024 – Present General Manager, WANTAI BIOPHARM

2022 – 2023 President, United Imaging Surgical Technologies Inc

2016 – 2022 Global VP & General Manager, Beckman Coulter/Danaher, China

2012 – 2016 Regional General Manager, Beckman Coulter/Danaher, Rest of Asia Pacific

2006 – 2012 Asia Pacific Marketing Director, Beckman Coulter/Danaher, Asia Pacific

2004 – 2006 Global Marketing Manager, Beckman Coulter/Danaher, Global Business

EDUCATION

1996 - 2001 Ph.D. University of California Los Angeles (UCLA)

1991 - 1995 B.S. Nankai University

As a representative for Corporate Members of IFCC, my intent is to leverage decades of cross-industry leadership and global healthcare expertise to address critical challenges and drive tangible impact. The corporate sector is the backbone of IFCC's mission, and my focus will center on five strategic priorities:

1. Enhancing Strategic Public-Private Collaboration

Lab medicine thrives at the intersection of innovation and regulation. My experience in shaping policies as Vice Chairman of CAIVD and CPCEM (detailed information is shown in Section 5.), combined with corporate leadership roles at Danaher and WANTAI, equips me to bridge public health agencies and private enterprises. This includes advocating for harmonized global standards (e.g., AI-driven diagnostic protocols) and fostering partnerships to accelerate technology translation—such as integrating AI tools into routine lab workflows via public-private R&C alliances.

2. Accelerating Technology Adoption & Integration

Emerging technologies like AI, digital twins, and large-language models are revolutionizing diagnostics, but adoption remains fragmented. As Secretary General of CAIDM, I led initiatives to embed AI in lab medicine, the lessons from which can scale globally through IFCC. My plan includes:

- Creating technology roadmaps for labs of all sizes, prioritizing cost-effective solutions for resource-constrained regions;
- Establishing IFCC-certified technology hubs to demo and validate innovations (e.g., AI-based result interpretation systems).

3. Driving Sustainable Laboratory Medicine

Sustainability in lab operations (e.g., energy efficiency, waste management, reagent optimization) is non-negotiable. I will propose:

- Global sustainability benchmarks for labs, aligned with EC regulations and WHO guidelines;
- A corporate-led initiative to recycle diagnostic equipment and share green technologies with low-income countries.

4. Navigating Regulatory & Market Landscapes

Divergent regulations hinder global access to innovative diagnostics. My working experience enables me to:

- Advocate for streamlined regulatory pathways (e.g., mutual recognition of diagnostic approvals);
- Support corporate members in navigating regional nuances, from China's NMPA to EU's IVDR.

5. Strengthening Global Outreach & Capacity Building

Equal access to lab medicine is a moral imperative. I advocate that:

- Launching regional training academies (APAC, Africa, LATAM) to build local expertise in advanced testing;

- Partnering with corporate members to donate the latest diagnostic tools to underserved communities, paired with technical training.

Corporate Members are not just stakeholders - they are architects of IFCC's future. With my blend of industry leadership, policy expertise, and cross-cultural collaboration, I will ensure your voices drive IFCC's strategy, from standard-setting to technology deployment. Together, we can transform laboratory medicine into a globally inclusive, technologically advanced, and patient-centric force.

5. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the Corporate Members. The statement should describe how your previous service will contribute to your success as a Corporate Member. Font used should be Calibri; font size 11.

Despite being a new participant for IFCC, I delivered a speech at the 2025 IFCC General Conference in Bruges and bring extensive experience in China's IVD industry. Below are my roles in four national organizations:

- Vice Chairman, China Association of In-Vitro Diagnostics (CAIVD)
- Vice Chairman, China Professional Community of Experimental Medicine (CPCEM)
- Vice Chairman & Secretary General, China Association of AI and Digital Twin Medicine (CAIDM)
- Council Member, Chinese Preventive Medicine Association (CPMA)

The China Association of In-Vitro Diagnostics (CAIVD) is the national organization representing the full spectrum of China's IVD industry, connecting over 2,000 manufacturers, distributors, agents, service providers, and other key industry players committed to advancing diagnostics and healthcare innovation.

Since assuming the role of Vice Chairman of CAIVD in October 2024, I have actively promoted member engagement international collaboration, and forward-looking strategies that align domestic industry development with global standards. China's IVD sector stands at a critical moment of transformation-driven by technological breakthroughs, digital health integration, and an expanding global outlook. In an increasingly complex and uncertain international environment, I believe it is more important than ever to promote mutual understanding, open dialogue, and cooperation across borders. Chinese companies are demonstrating a growing commitment to global responsibility, and I am proud to support platforms that foster meaningful exchange with the international scientific community.

The China Professional Community of Experimental Medicine (CPCEM), with over 900 expert members from hospitals, independent laboratories, universities, and research institutions, serves as a vibrant platform for academic exchange. Since April 2024, I have supported its mission to bridge research and clinical practice, especially in translating experimental advances into impactful diagnostics innovation.

In April 2025, recognizing the transformative potential of digital technologies, I led efforts to establish the China Association of Artificial Intelligence and Digital Twin Medicine (CAIDM). As Vice Chairman, I work to accelerate the adoption of AI in diagnostics through interdisciplinary partnerships and data-driven innovation.

I believe IFCC is uniquely positioned to unite countries, harmonize standards, and ensure shared access to emerging technologies. If entrusted with the role of Corporate Representative, I will advocate for stronger collaboration between global corporates and scientific leaders. At the same time, I will bring forward the collective perspective of China's diagnostics industry - an increasingly active, innovative, and globally minded community. By bridging corporate and international voices, I hope to contribute to IFCC's vision of a future where laboratory medicine can drive healthcare from disease management towards intelligent health management. Together, we can shape a more connected, inclusive, and resilient global diagnostics ecosystem.

6. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the Corporate Members. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

My professional and academic pursuits are intricately aligned with the multifaceted mission of IFCC. With over two decades of leadership in the IVD industry and diverse academic roles, I am committed to driving innovation, standardization, and global collaboration within laboratory medicine.

As a former global executive at Beckman Coulter/Danaher and current GM of WANTAI BIOPHARM, I have a proven track record in scaling diagnostic technologies and navigating international markets. This experience equips me to actively contribute to IFCC's goal of promoting scientific excellence. I can support research initiatives, particularly in the development of AI - driven diagnostic methods, similar to my work leading AI integration projects at CAIDM. Additionally, my expertise in global operations can aid in establishing consistent international standards, ensuring accuracy and reliability of laboratory results worldwide, much like IFCC's efforts in standardizing biomarker measurements.

In my roles as Vice Chairman of CAIVD and CPCEM, I have been deeply involved in shaping IVD policies and professional standards in China. This background positions me well to enhance quality and safety in laboratory medicine, in line with IFCC's mission. I can advocate for best practices in quality management, accreditation, and patient safety, drawing on my experience in regulatory compliance and error - reduction strategies.

My tenure at United Imaging emphasized sustainable lab operations, which aligns with IFCC's focus on global health challenges. I can contribute to initiatives aimed at promoting access to diagnostics, especially in resource - constrained regions, and coordinating laboratory responses during public health crises.

As a Council Member of CPMA, I have prioritized preventive care through lab medicine. This perspective enables me to support IFCC's educational programs, ensuring that laboratory professionals are equipped with the latest knowledge to drive proactive health management. Moreover, my cross - cultural experience in the APAC and global markets allows me to facilitate international collaboration, knowledge sharing, and ethical standard - setting, all of which are crucial for realizing IFCC's overarching mission of advancing laboratory medicine for the betterment of global healthcare.



Lucy LIU

SNIBE - SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.



NOMINATION FORM for CORPORATE REPRESENTATIVE IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination

On behalf of: **Snibe-Shenzhen New Industries Biomedical Engineering Co., Ltd.**

(Please insert name of your company)

a Corporate Member of the International Federation of Clinical Chemistry and Laboratory Medicine,

I nominate: **Vice President of Snibe, Lucy Liu**

No. 23, Snibe Building, Jinxiu East Road, Pingshan District, 518122 Shenzhen P.R. China

to the position of **Corporate Representative on IFCC Executive Board for the term 2027-2029.**

Vincent Chen / Head of Global Marketing of Snibe

Signature: Vincent Chen

Date: 2025 - June - 30

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I, **Lucy Liu**

accept the above nomination. I declare that I am an employee of a Corporate Member of IFCC.

Signature: [Signature] Date: 2025. 6. 30.

Signature Date

3. Consent by Nominee's Employer

On behalf of: **Snibe-Shenzhen New Industries Biomedical Engineering Co., Ltd.**

I confirm that we consent to the above nomination to the position of **Corporate Representative on IFCC Executive Board for the term 2027-2029.**

Name: **Dr. Rao Wei**

Position in Company: **Chairman and General Manager of Snibe**

Signature: [Signature] Date: 2025. 6. 30.

Signature Date

4. Statement of Intent

As Vice President of Snibe Diagnostics, I have been instrumental in establishing the company as one of China's foremost and internationally recognized in-vitro diagnostics manufacturers, with our products serving healthcare institutions across more than 160 countries. I deeply value the IFCC's pivotal role in advancing global laboratory medicine and am steadfastly dedicated to furthering the Federation's mission.

In my view, corporate members are not merely sponsors but essential collaborators in advancing the IFCC's scientific, educational, and public health objectives. Should I be elected, my priorities will include fostering transparent and robust communication between corporate members and IFCC leadership, as well as enhancing engagement opportunities—particularly for emerging enterprises and those from developing regions. I am equally committed to amplifying the visibility and influence of corporate members, ensuring their contributions align with the IFCC's overarching goal of elevating laboratory science and patient care worldwide.

If entrusted with this responsibility, I commit to fulfilling the following duties in alignment with the IFCC Executive Board Corporate Representative's role:

1. Time Commitment & Accountability

-Dedicate the required at least 10 hours per week to IFCC tasks. Should unforeseen circumstances limit my availability, As the Vice President of the company, I will coordinate with my team easily to ensure responsibilities are seamlessly covered without disrupting my IFCC tasks.

2. Maximizing Benefits for Corporate Members

-Serve as the primary interface between Corporate Members and the Executive Board, ensuring their questions and needs are addressed.
-Advocate for Corporate Member interests in IFCC plans and activities, leveraging my experience as a long-standing supporter of IFCC conferences to secure tangible returns.

3. Representing Diverse Member Interests

-Champion the concerns of small and medium-sized corporate members (like Snibe), ensuring their voices are heard in Executive Board discussions.
-Balance the needs of all Corporate Members, regardless of size, to foster inclusive decision-making.

4. Enhancing Engagement & Collaboration

-Proactively encourage Corporate Member participation in IFCC activities and functional units.
-Address inactivity by facilitating regular communication, such as liaising with the IFCC Task Force Corporate Members and organizing dedicated forums (e.g., IVD sector networking platforms) to discuss industry challenges.

5. Expanding Corporate Membership

-Actively recruit new Corporate Members by promoting IFCC's value proposition and assisting new companies in understanding membership benefits.

6. Operational Responsibilities

-Manage Corporate Member correspondence in collaboration with the IFCC Office, ensuring timely and secure communication.

Above all, I pledge to serve as an impartial advocate for the IVD community within the IFCC Executive Board, prioritizing collective progress over any singular corporate interest, and adhering strictly to the responsibilities outlined by the IFCC.

5. Statement of Service

Since Snibe Diagnostics became a Corporate Member of IFCC 12 years ago, I have played an active and leading role in our company's engagement with IFCC activities and its regional federations, including the Asia-Pacific Federation of Clinical Biochemistry and Laboratory Medicine (APFCB). Under my leadership, Snibe has consistently supported IFCC congresses, educational programs, and scientific initiatives, reinforcing the importance of corporate partnerships in advancing IFCC's strategic mission.

As a prominent corporate sponsor, Snibe has made substantial contributions to IFCC's academic programs and major international conferences worldwide, including support for the scientific programs of WorldLab, EuroMedLab, and regional meetings such as APFCB, COLABIOCLI, EFLM, and AFCC, as well as numerous national society congresses. I have facilitated the development of multiple academic collaborations between Snibe and IFCC member societies and regional federations. Through these efforts, we have contributed to the promotion of harmonization, quality assurance standards, and innovation in clinical laboratory medicine.

Additionally, I have demonstrated a strong commitment to the development of young scientists by supporting travel grants, fellowships, and educational initiatives, including sponsorship of the IFCC Young Scientist Award. I have also championed programs that assist both early-career and established researchers through training and knowledge exchange initiatives. My experience in bridging industry and the scientific community highlights my dedication to advancing global laboratory medicine.

6. Statement of Interests

I serve as Vice President of Snibe Diagnostics, headquartered in Shenzhen, China. In my capacity as Vice President of Snibe Diagnostics, I have overseen the development of a comprehensive portfolio of immunoassay, clinical chemistry, and laboratory automation solutions, now deployed worldwide. My professional focus centers on pioneering diagnostic technologies that enhance clinical decision-making and healthcare accessibility on a global scale.

I am deeply committed to elevating the recognition of laboratory medicine as a critical component of modern healthcare. I strongly believe in fostering collaborative partnerships among industry, academia, and clinical laboratories to support IFCC's global leadership in our field.

If given the opportunity, I will continue to advocate for robust corporate engagement in IFCC's scientific and educational mission. Together, we can drive meaningful and valuable progress in laboratory medicine worldwide.



Tricia RAVALICO

ABBOTT DIAGNOSTICS



NOMINATION FORM for CORPORATE REPRESENTATIVE

IFCC EXECUTIVE BOARD 2027-2029

To be sent via e-mail to the IFCC Office at ifcc@ifcc.org

1. Nomination

On behalf of :**ABBOTT**.....
a Corporate Member of the International Federation of Clinical Chemistry and Laboratory Medicine,

I nominate:**Tricia Ravalico**.....

.....**Director, Scientific Leadership and Education**.....

.....**Abbott, CORE Diagnostics...Email: Tricia,Ravalico@abbott.com**

to the position of **Corporate Representative on IFCC Executive Board for the term 2027-2029.**

Self-nominated by Tricia Ravalico, as Abbott's Corporate's Representative
(Please insert your own name and position within the company)

Signature:..... *Tricia Ravalico*

Date:**June 5, 2025**.....

A recent picture should be provided, however a full curriculum vitae is not required.

2. Acceptance by Nominee

I,
Tricia Ravalico
accepts the above nomination. I declare that I am an employee of a Corporate Member of IFCC.

Tricia Ravalico**June 5, 2025**.....
Signature Date

3. Consent by Nominee's Employer

On behalf of:**Abbott**.....

I confirm that we consent to the above nomination to the position of **Corporate Representative on IFCC Executive Board for the term 2027-2029.**

Name:**Alex Carterson, MD, PhD**.....

Position in Company:**Divisional Vice President, Medical Affairs**.....

Alex Carterson**June 5, 2025**.....
Signature Date



4. Statement of Intent

Please supply a statement of intent (max 500 words) for circulation to the Corporate Members. The statement should outline issues which you see as important for the IFCC and how you might address them. Font used should be Calibri; font size 11.

Abbott was recognized this year (among 3 other companies) for 45-years of legacy collaborations with the IFCC. As an employee of Abbott for nearly 3-decades, I support and embrace everything that the IFCC stands for, including its mission to advance excellence in laboratory medicine for better healthcare worldwide.

My intent in seeking a second term as Corporate Representative on the Executive Board is to continue building and sustaining legacy collaborations with the IFCC and its corporate members. Working together... not as vendors, competitors or simply 'sponsors', but as partners who advocate, problem-solve and innovate by going farther together.

As a leader, I believe in fair and transparent communications. I believe in honesty, teamwork, and accountability. I have been honored to twice chair the Task Force of Corporate Members, and have been actively learning how to best advance the needs of our corporate members for the betterment of our companies, the IFCC and laboratory medicine overall.

While we have made great strides in corporate member engagement, we still have farther to go. With more corporate members joining each year, there are members still wanting to become more involved. There are other members who seek different benefits from the IFCC, as some of us represent scientific initiatives whereas others are commercially focused. There are platforms within the IFCC that enable all of these needs and more, so a major focus of my second term will be focused on how to better educate on maximizing the benefits of IFCC engagement.

I am excited about the future and would be honored to serve as the Corporate Member voice on the IFCC Executive Board for the 2027-2029 term.

5. Statement of Service

Please supply a statement of previous service within IFCC, national or regional organisations (max 400 words) for circulation to the Corporate Members. The statement should describe how your previous service will contribute to your success as a Corporate Member. Font used should be Calibri; font size 11.

Tricia has been the IFCC Corporate Representative for Abbott since 2017. At that time, Abbott had limited engagement within the IFCC. Under Tricia's leadership, Abbott's participation in IFCC doubled, spanning newly nominated Abbott members and corresponding members for IFCC committees, working groups and task forces. To date, Abbott remains one of the strongest supporters of IFCC through resource representation across IFCC divisions.

Tricia was proud to serve 2 terms (6 years) as the Corporate Representative to the Communications and Publications Division (CPD). During that window, she also became Chair of the IFCC Task Force (TF) of Corporate Members (CM). The latter position was of extreme interest to Tricia upon task force inception, but her commitment to the CPD prevented her from an initial leadership role.

When the inaugural chair the TF-CMs stepped down to become the Corporate Representative on the Executive Board, Tricia received an exception to serve in both roles. During that time, she stepped established a new and frequent meeting cadence, removed inactive CMs, developed a valued welcome package, certificate program and initiated annual corporate member surveys.

In 2024, Tricia was elected to be the Corporate Representative of the IFCC Executive Board (EB). She stepped down as the Chair of the IFCC TF-CM to accept the honor of being part of the IFCC EB. One year later, however, when her successor stepped down, Tricia resumed her role as Chair of the TF-CMs at the appointment of IFCC President, Tomris Ozben.

In addition to these roles, Tricia has volunteered to support various working groups, maintains a consulting role to the CPR committee, is active in IFCC eNEWs, and was even an assistant editor for a special issue of the eJIFCC. Her longest role on an IFCC committee includes corresponding membership with the CCB. Her recent leadership within the CCB led to a new initiative launched in 2025 with IFCC leaders answering the most commonly asked questions in the field of cardiac diagnostics today. Former initiatives in this area included educational lectures at major conferences with up to 6 collaborative industry sponsors.

6. Statement of Interests

Please supply a statement of major professional, scientific or clinical interests (max 400 words) for circulation to the Corporate Members. The statement should describe how your previous interests will contribute to the mission of IFCC. Font used should be Calibri; font size 11.

I am passionate about health, and since insights from laboratory medicine are essential for health, I am even more passionate about laboratory medicine.

A sad reality, however, is that laboratory medicine is not always recognized for its essential role in advancing healthcare. It is under-funded, under-appreciated, and under-utilized. With that said, optimization of new care pathways enabled through laboratory medicine is the answer to most unmet needs. This is why I am passionate about the future of laboratory medicine and in the power we all have to advance the mission of the IFCC.

One of the major ways that I fuel the above passion is through the UNIVANTS of Healthcare Excellence award program. The latter recognizes healthcare teams who have achieved measurably better healthcare performance through laboratory-enabled best practices. The IFCC is a proud partner of this initiative, and was in fact, the first among the founding partners to join the initiative. Since inception, the program has now recognized 85 lab-enabled best practices in healthcare. Winners of the award include experts, advocates and leaders throughout the IFCC family and across 165 countries.

I have authored multiple articles in this area include annual reflection pieces in JALM and a depicted special issue in the eJIFCC.

Other research passions of mine are in the field of cardiac diagnostics. The latter might explain why I have been so active in the IFCC CCB which includes writing an article for the IFCC eNEWS on behalf of that work as recently as last month.

And finally, I believe in amplifying the value of laboratory medicine. This is why I am still active with the CPR and recently created 4 videos across companies elevating the value of lab medicine (2 lab week videos), highlighting the importance of the IFCC (2 IFCC videos among division leaders and volunteers) and an Abbott video celebrating 45 years of legacy partnerships.